ID   CO5_HUMAN               Reviewed;        1676 AA.
AC   P01031; Q14CJ0; Q27I61;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   05-FEB-2008, sequence version 4.
DT   18-JUL-2018, entry version 208.
DE   RecName: Full=Complement C5;
DE   AltName: Full=C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4;
DE   Contains:
DE     RecName: Full=Complement C5 beta chain;
DE   Contains:
DE     RecName: Full=Complement C5 alpha chain;
DE   Contains:
DE     RecName: Full=C5a anaphylatoxin;
DE   Contains:
DE     RecName: Full=Complement C5 alpha' chain;
DE   Flags: Precursor;
GN   Name=C5; Synonyms=CPAMD4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ILE-389 AND ILE-802.
RX   PubMed=1984448;
RA   Haviland D.L., Haviland J.C., Fleischer D.T., Hunt A., Wetsel R.A.;
RT   "Complete cDNA sequence of human complement pro-C5. Evidence of
RT   truncated transcripts derived from a single copy gene.";
RL   J. Immunol. 146:362-368(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-145; GLY-449;
RP   ILE-802; GLN-928; VAL-933; THR-1033; ASN-1037; LYS-1043; ASN-1310 AND
RP   ASP-1437.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (FEB-2006) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ILE-802.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-802.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 412-1676, AND VARIANT ILE-802.
RX   PubMed=3365401; DOI=10.1021/bi00405a012;
RA   Wetsel R.A., Lemons R.S., Lebeau M.M., Barnum S.R., Noack D.,
RA   Tack B.F.;
RT   "Molecular analysis of human complement component C5: localization of
RT   the structural gene to chromosome 9.";
RL   Biochemistry 27:1474-1482(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 412-1676, AND VARIANT ILE-802.
RX   PubMed=2579066;
RA   Lundwall A.B., Wetsel R.A., Kristensen T., Whitehead A.S., Woods D.E.,
RA   Ogden R.C., Colten H.R., Tack B.F.;
RT   "Isolation and sequence analysis of a cDNA clone encoding the fifth
RT   complement component.";
RL   J. Biol. Chem. 260:2108-2112(1985).
RN   [7]
RP   PROTEIN SEQUENCE OF 678-751.
RX   PubMed=690134;
RA   Fernandez H.N., Hugli T.E.;
RT   "Primary structural analysis of the polypeptide portion of human C5a
RT   anaphylatoxin. Polypeptide sequence determination and assignment of
RT   the oligosaccharide attachment site in C5a.";
RL   J. Biol. Chem. 253:6955-6964(1978).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 678-751.
RX   PubMed=1996961; DOI=10.1042/bj2730635;
RA   Bohnsack J.F., Mollison K.W., Buko A.M., Ashworth J.C., Hill H.R.;
RT   "Group B streptococci inactivate complement component C5a by enzymic
RT   cleavage at the C-terminus.";
RL   Biochem. J. 273:635-640(1991).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH C5AR1.
RX   PubMed=8182049;
RA   DeMartino J.A., Van Riper G., Siciliano S.J., Molineaux C.J.,
RA   Konteatis Z.D., Rosen H., Springer M.S.;
RT   "The amino terminus of the human C5a receptor is required for high
RT   affinity C5a binding and for receptor activation by C5a but not C5a
RT   analogs.";
RL   J. Biol. Chem. 269:14446-14450(1994).
RN   [10]
RP   INTERACTION WITH C5AR1.
RX   PubMed=9553099; DOI=10.1074/jbc.273.17.10411;
RA   Chen Z., Zhang X., Gonnella N.C., Pellas T.C., Boyar W.C., Ni F.;
RT   "Residues 21-30 within the extracellular N-terminal region of the C5a
RT   receptor represent a binding domain for the C5a anaphylatoxin.";
RL   J. Biol. Chem. 273:10411-10419(1998).
RN   [11]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-741; ASN-911 AND ASN-1630.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [12]
RP   STRUCTURE BY NMR OF C5A.
RX   PubMed=3408713; DOI=10.1021/bi00410a007;
RA   Zuiderweg E.R.P., Mollison K.W., Henkin J., Carter G.W.;
RT   "Sequence-specific assignments in the 1H NMR spectrum of the human
RT   inflammatory protein C5a.";
RL   Biochemistry 27:3568-3580(1988).
RN   [13]
RP   STRUCTURE BY NMR OF C5A.
RX   PubMed=2784981; DOI=10.1021/bi00427a025;
RA   Zuiderweg E.R.P., Nettesheim D.G., Mollison K.W., Carter G.W.;
RT   "Tertiary structure of human complement component C5a in solution from
RT   nuclear magnetic resonance data.";
RL   Biochemistry 28:172-185(1989).
RN   [14]
RP   STRUCTURE BY NMR OF C5A.
RX   PubMed=2730871; DOI=10.1021/bi00432a008;
RA   Zuiderweg E.R.P., Fesik S.W.;
RT   "Heteronuclear three-dimensional NMR spectroscopy of the inflammatory
RT   protein C5a.";
RL   Biochemistry 28:2387-2391(1989).
RN   [15]
RP   STRUCTURE BY NMR OF 679-747 OF C5A, AND DISULFIDE BONDS.
RX   PubMed=9007977; DOI=10.1002/pro.5560060107;
RA   Zhang X., Boyar W., Galakatos N., Gonnella N.C.;
RT   "Solution structure of a unique C5a semi-synthetic antagonist:
RT   implications in receptor binding.";
RL   Protein Sci. 6:65-72(1997).
RN   [16]
RP   STRUCTURE BY NMR OF 679-751 OF C5A, AND DISULFIDE BONDS.
RX   PubMed=9188742;
RX   DOI=10.1002/(SICI)1097-0134(199706)28:2<261::AID-PROT13>3.0.CO;2-G;
RA   Zhang X., Boyar W., Toth M.J., Wennogle L., Gonnella N.C.;
RT   "Structural definition of the C5a C-terminus by two-dimensional
RT   nuclear magnetic resonance spectroscopy.";
RL   Proteins 28:261-267(1997).
RN   [17]
RP   INVOLVEMENT IN COMPLEMENT C5 DEFICIENCY.
RX   PubMed=7730648;
RA   Wang X., Fleischer D.T., Whitehead W.T., Haviland D.L.,
RA   Rosenfeld S.I., Leddy J.P., Snyderman R., Wetsel R.A.;
RT   "Inherited human complement C5 deficiency. Nonsense mutations in exons
RT   1 (Gln1 to Stop) and 36 (Arg1458 to Stop) and compound heterozygosity
RT   in three African-American families.";
RL   J. Immunol. 154:5464-5471(1995).
RN   [18]
RP   INVOLVEMENT IN COMPLEMENT C5 DEFICIENCY.
RX   PubMed=15778377; DOI=10.4049/jimmunol.174.7.4172;
RA   Pfarr N., Prawitt D., Kirschfink M., Schroff C., Knuf M.,
RA   Habermehl P., Mannhardt W., Zepp F., Fairbrother W., Loos M.,
RA   Burge C.B., Pohlenz J.;
RT   "Linking C5 deficiency to an exonic splicing enhancer mutation.";
RL   J. Immunol. 174:4172-4177(2005).
RN   [19]
RP   INVOLVEMENT IN COMPLEMENT C5 DEFICIENCY, AND VARIANTS ILE-389 AND
RP   ILE-802.
RX   PubMed=15488949; DOI=10.1016/S0161-5890(04)00255-X;
RA   Delgado-Cervino E., Fontan G., Lopez-Trascasa M.;
RT   "C5 complement deficiency in a Spanish family. Molecular
RT   characterization of the double mutation responsible for the defect.";
RL   Mol. Immunol. 42:105-111(2005).
RN   [20]
RP   ASSOCIATION WITH SUSCEPTIBILITY TO LIVER FIBROSIS.
RX   PubMed=15995705; DOI=10.1038/ng1599;
RA   Hillebrandt S., Wasmuth H.E., Weiskirchen R., Hellerbrand C.,
RA   Keppeler H., Werth A., Schirin-Sokhan R., Wilkens G., Geier A.,
RA   Lorenzen J., Koehl J., Gressner A.M., Matern S., Lammert F.;
RT   "Complement factor 5 is a quantitative trait gene that modifies liver
RT   fibrogenesis in mice and humans.";
RL   Nat. Genet. 37:835-843(2005).
RN   [21]
RP   STRUCTURE BY NMR OF 1530-1676, AND DISULFIDE BONDS.
RX   PubMed=15598652; DOI=10.1074/jbc.M413126200;
RA   Bramham J., Thai C.-T., Soares D.C., Uhrin D., Ogata R.T.,
RA   Barlow P.N.;
RT   "Functional insights from the structure of the multifunctional C345C
RT   domain of C5 of complement.";
RL   J. Biol. Chem. 280:10636-10645(2005).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS), INTERACTION WITH TICK
RP   COMPLEMENT INHIBITOR, GLYCOSYLATION AT ASN-741 AND ASN-911, AND
RP   DISULFIDE BONDS.
RX   PubMed=18536718; DOI=10.1038/ni.1625;
RA   Fredslund F., Laursen N.S., Roversi P., Jenner L., Oliveira C.L.P.,
RA   Pedersen J.S., Nunn M.A., Lea S.M., Discipio R., Sottrup-Jensen L.,
RA   Andersen G.R.;
RT   "Structure of and influence of a tick complement inhibitor on human
RT   complement component 5.";
RL   Nat. Immunol. 9:753-760(2008).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (4.30 ANGSTROMS) OF 20-1676 IN COMPLEX WITH
RP   COBRA VENOM FACTOR, GLYCOSYLATION AT ASN-911, AND DISULFIDE BONDS.
RX   PubMed=21217642; DOI=10.1038/emboj.2010.341;
RA   Laursen N.S., Andersen K.R., Braren I., Spillner E.,
RA   Sottrup-Jensen L., Andersen G.R.;
RT   "Substrate recognition by complement convertases revealed in the C5-
RT   cobra venom factor complex.";
RL   EMBO J. 30:606-616(2011).
RN   [24]
RP   VARIANT TYR-966, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22028381; DOI=10.1093/jmcb/mjr024;
RA   Su Z.D., Sun L., Yu D.X., Li R.X., Li H.X., Yu Z.J., Sheng Q.H.,
RA   Lin X., Zeng R., Wu J.R.;
RT   "Quantitative detection of single amino acid polymorphisms by targeted
RT   proteomics.";
RL   J. Mol. Cell Biol. 3:309-315(2011).
RN   [25]
RP   VARIANTS CYS-885 AND HIS-885, AND INVOLVEMENT IN POOR RESPONSE TO
RP   ECULIZUMAB.
RX   PubMed=24521109; DOI=10.1056/NEJMoa1311084;
RA   Nishimura J., Yamamoto M., Hayashi S., Ohyashiki K., Ando K.,
RA   Brodsky A.L., Noji H., Kitamura K., Eto T., Takahashi T., Masuko M.,
RA   Matsumoto T., Wano Y., Shichishima T., Shibayama H., Hase M., Li L.,
RA   Johnson K., Lazarowski A., Tamburini P., Inazawa J., Kinoshita T.,
RA   Kanakura Y.;
RT   "Genetic variants in C5 and poor response to eculizumab.";
RL   N. Engl. J. Med. 370:632-639(2014).
CC   -!- FUNCTION: Activation of C5 by a C5 convertase initiates the
CC       spontaneous assembly of the late complement components, C5-C9,
CC       into the membrane attack complex. C5b has a transient binding site
CC       for C6. The C5b-C6 complex is the foundation upon which the lytic
CC       complex is assembled.
CC   -!- FUNCTION: Derived from proteolytic degradation of complement C5,
CC       C5 anaphylatoxin is a mediator of local inflammatory process.
CC       Binding to the receptor C5AR1 induces a variety of responses
CC       including intracellular calcium release, contraction of smooth
CC       muscle, increased vascular permeability, and histamine release
CC       from mast cells and basophilic leukocytes (PubMed:8182049). C5a is
CC       also a potent chemokine which stimulates the locomotion of
CC       polymorphonuclear leukocytes and directs their migration toward
CC       sites of inflammation. {ECO:0000269|PubMed:8182049}.
CC   -!- SUBUNIT: C5 precursor is first processed by the removal of 4 basic
CC       residues, forming two chains, beta and alpha, linked by a
CC       disulfide bond. C5 convertase activates C5 by cleaving the alpha
CC       chain, releasing C5a anaphylatoxin and generating C5b (beta chain
CC       + alpha' chain). The C5a anaphylatoxin interacts with C5AR1.
CC       Interacts with tick complement inhibitor.
CC       {ECO:0000269|PubMed:18536718, ECO:0000269|PubMed:21217642,
CC       ECO:0000269|PubMed:8182049, ECO:0000269|PubMed:9553099}.
CC   -!- INTERACTION:
CC       Q91132:- (xeno); NbExp=2; IntAct=EBI-8558308, EBI-7081824;
CC       Q96BA8:CREB3L1; NbExp=3; IntAct=EBI-8558308, EBI-6942903;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- POLYMORPHISM: C5 variants are responsible for poor response to
CC       eculizumab [MIM:615749]. Eculizumab is a monoclonal antibody
CC       highly effective in reducing intravascular hemolysis in patients
CC       with paroxysmal nocturnal hemoglobinuria. It specifically binds to
CC       the terminal complement protein C5, inhibits its cleavage into C5a
CC       and C5b, and prevents the formations of the cytolytic complement
CC       pore (PubMed:24521109). {ECO:0000269|PubMed:24521109}.
CC   -!- DISEASE: Complement component 5 deficiency (C5D) [MIM:609536]: A
CC       rare defect of the complement classical pathway associated with
CC       susceptibility to severe recurrent infections, predominantly by
CC       Neisseria gonorrhoeae or Neisseria meningitidis. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Note=An association study of C5 haplotypes and genotypes
CC       in individuals with chronic hepatitis C virus infection shows that
CC       individuals homozygous for the C5_1 haplotype have a significantly
CC       higher stage of liver fibrosis than individuals carrying at least
CC       1 other allele. {ECO:0000269|PubMed:15995705}.
CC   -!- WEB RESOURCE: Name=C5base; Note=C5 mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/C5base/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Complement C5 entry;
CC       URL="https://en.wikipedia.org/wiki/Complement_component_5";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/c5/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; M57729; AAA51925.1; -; mRNA.
DR   EMBL; DQ400449; ABD48959.1; -; Genomic_DNA.
DR   EMBL; CH471090; EAW87480.1; -; Genomic_DNA.
DR   EMBL; BC113738; AAI13739.1; -; mRNA.
DR   EMBL; BC113740; AAI13741.1; -; mRNA.
DR   EMBL; M65134; AAA51856.1; -; mRNA.
DR   CCDS; CCDS6826.1; -.
DR   PIR; A40075; C5HU.
DR   RefSeq; NP_001304092.1; NM_001317163.1.
DR   RefSeq; NP_001726.2; NM_001735.2.
DR   UniGene; Hs.494997; -.
DR   PDB; 1CFA; NMR; -; A=679-747.
DR   PDB; 1KJS; NMR; -; A=679-751.
DR   PDB; 1XWE; NMR; -; A=1530-1676.
DR   PDB; 3CU7; X-ray; 3.10 A; A/B=1-1676.
DR   PDB; 3HQA; X-ray; 2.59 A; A/B=679-750.
DR   PDB; 3HQB; X-ray; 3.30 A; A/B=679-750.
DR   PDB; 3KLS; X-ray; 3.60 A; A/B=1-1676.
DR   PDB; 3KM9; X-ray; 4.20 A; A/B=1-1676.
DR   PDB; 3PRX; X-ray; 4.30 A; A/C=1-1676.
DR   PDB; 3PVM; X-ray; 4.30 A; A/C=1-1676.
DR   PDB; 4A5W; X-ray; 3.50 A; A=19-1676.
DR   PDB; 4E0S; X-ray; 4.21 A; A=1-1676.
DR   PDB; 4P39; X-ray; 2.40 A; A/B/C/D=678-747.
DR   PDB; 4UU9; X-ray; 2.12 A; C/D=678-751.
DR   PDB; 5B4P; X-ray; 2.40 A; B/D=678-751.
DR   PDB; 5B71; X-ray; 2.11 A; E/F=20-124.
DR   PDB; 5HCC; X-ray; 2.59 A; A=679-1676, B=19-674.
DR   PDB; 5HCD; X-ray; 2.98 A; A=679-1676, B=19-674.
DR   PDB; 5HCE; X-ray; 3.12 A; A=679-1676, B=19-674.
DR   PDB; 5I5K; X-ray; 4.20 A; A/B=1-1676.
DR   PDBsum; 1CFA; -.
DR   PDBsum; 1KJS; -.
DR   PDBsum; 1XWE; -.
DR   PDBsum; 3CU7; -.
DR   PDBsum; 3HQA; -.
DR   PDBsum; 3HQB; -.
DR   PDBsum; 3KLS; -.
DR   PDBsum; 3KM9; -.
DR   PDBsum; 3PRX; -.
DR   PDBsum; 3PVM; -.
DR   PDBsum; 4A5W; -.
DR   PDBsum; 4E0S; -.
DR   PDBsum; 4P39; -.
DR   PDBsum; 4UU9; -.
DR   PDBsum; 5B4P; -.
DR   PDBsum; 5B71; -.
DR   PDBsum; 5HCC; -.
DR   PDBsum; 5HCD; -.
DR   PDBsum; 5HCE; -.
DR   PDBsum; 5I5K; -.
DR   ProteinModelPortal; P01031; -.
DR   SMR; P01031; -.
DR   BioGrid; 107188; 8.
DR   IntAct; P01031; 11.
DR   MINT; P01031; -.
DR   STRING; 9606.ENSP00000223642; -.
DR   ChEMBL; CHEMBL2364163; -.
DR   DrugBank; DB01257; Eculizumab.
DR   DrugBank; DB00028; Immune Globulin Human.
DR   MEROPS; I39.952; -.
DR   CarbonylDB; P01031; -.
DR   iPTMnet; P01031; -.
DR   PhosphoSitePlus; P01031; -.
DR   BioMuta; C5; -.
DR   DMDM; 166900096; -.
DR   EPD; P01031; -.
DR   MaxQB; P01031; -.
DR   PaxDb; P01031; -.
DR   PeptideAtlas; P01031; -.
DR   PRIDE; P01031; -.
DR   ProteomicsDB; 12624; -.
DR   ProteomicsDB; 51309; -.
DR   Ensembl; ENST00000223642; ENSP00000223642; ENSG00000106804.
DR   GeneID; 727; -.
DR   KEGG; hsa:727; -.
DR   UCSC; uc004bkv.4; human.
DR   CTD; 727; -.
DR   DisGeNET; 727; -.
DR   EuPathDB; HostDB:ENSG00000106804.7; -.
DR   GeneCards; C5; -.
DR   H-InvDB; HIX0025739; -.
DR   HGNC; HGNC:1331; C5.
DR   HPA; HPA029339; -.
DR   MalaCards; C5; -.
DR   MIM; 120900; gene.
DR   MIM; 609536; phenotype.
DR   MIM; 615749; phenotype.
DR   neXtProt; NX_P01031; -.
DR   OpenTargets; ENSG00000106804; -.
DR   Orphanet; 169150; Immunodeficiency due to a late component of complements deficiency.
DR   PharmGKB; PA25911; -.
DR   eggNOG; KOG1366; Eukaryota.
DR   eggNOG; ENOG410XRED; LUCA.
DR   GeneTree; ENSGT00760000118982; -.
DR   HOGENOM; HOG000231860; -.
DR   HOVERGEN; HBG098067; -.
DR   InParanoid; P01031; -.
DR   KO; K03994; -.
DR   OMA; YYIVTGE; -.
DR   OrthoDB; EOG091G00BU; -.
DR   PhylomeDB; P01031; -.
DR   TreeFam; TF313285; -.
DR   BRENDA; 3.4.21.43; 2681.
DR   Reactome; R-HSA-166665; Terminal pathway of complement.
DR   Reactome; R-HSA-174577; Activation of C3 and C5.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-977606; Regulation of Complement cascade.
DR   SIGNOR; P01031; -.
DR   EvolutionaryTrace; P01031; -.
DR   GeneWiki; Complement_component_5; -.
DR   GenomeRNAi; 727; -.
DR   PMAP-CutDB; P01031; -.
DR   PRO; PR:P01031; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000106804; -.
DR   CleanEx; HS_C5; -.
DR   Genevisible; P01031; HS.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; TAS:ProtInc.
DR   GO; GO:0005579; C:membrane attack complex; IDA:UniProtKB.
DR   GO; GO:0008009; F:chemokine activity; TAS:ProtInc.
DR   GO; GO:0004866; F:endopeptidase inhibitor activity; IEA:InterPro.
DR   GO; GO:0005102; F:signaling receptor binding; TAS:ProtInc.
DR   GO; GO:0000187; P:activation of MAPK activity; TAS:ProtInc.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0006935; P:chemotaxis; TAS:ProtInc.
DR   GO; GO:0006957; P:complement activation, alternative pathway; IEA:UniProtKB-KW.
DR   GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW.
DR   GO; GO:0019835; P:cytolysis; IEA:UniProtKB-KW.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; TAS:ProtInc.
DR   GO; GO:0010760; P:negative regulation of macrophage chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0090197; P:positive regulation of chemokine secretion; IDA:BHF-UCL.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; IDA:BHF-UCL.
DR   GO; GO:0030449; P:regulation of complement activation; TAS:Reactome.
DR   Gene3D; 2.60.40.10; -; 2.
DR   Gene3D; 2.60.40.690; -; 1.
DR   InterPro; IPR009048; A-macroglobulin_rcpt-bd.
DR   InterPro; IPR036595; A-macroglobulin_rcpt-bd_sf.
DR   InterPro; IPR011626; A2M_comp.
DR   InterPro; IPR002890; A2M_N.
DR   InterPro; IPR011625; A2M_N_2.
DR   InterPro; IPR000020; Anaphylatoxin/fibulin.
DR   InterPro; IPR018081; Anaphylatoxin_comp_syst.
DR   InterPro; IPR001840; Anaphylatoxn_comp_syst_dom.
DR   InterPro; IPR037562; Complement_C5.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR001599; Macroglobln_a2.
DR   InterPro; IPR001134; Netrin_domain.
DR   InterPro; IPR018933; Netrin_module_non-TIMP.
DR   InterPro; IPR008930; Terpenoid_cyclase/PrenylTrfase.
DR   InterPro; IPR008993; TIMP-like_OB-fold.
DR   PANTHER; PTHR11412:SF83; PTHR11412:SF83; 1.
DR   Pfam; PF00207; A2M; 1.
DR   Pfam; PF07678; A2M_comp; 1.
DR   Pfam; PF01835; A2M_N; 1.
DR   Pfam; PF07703; A2M_N_2; 1.
DR   Pfam; PF07677; A2M_recep; 1.
DR   Pfam; PF01821; ANATO; 1.
DR   Pfam; PF01759; NTR; 1.
DR   PRINTS; PR00004; ANAPHYLATOXN.
DR   SMART; SM01360; A2M; 1.
DR   SMART; SM01359; A2M_N_2; 1.
DR   SMART; SM01361; A2M_recep; 1.
DR   SMART; SM00104; ANATO; 1.
DR   SMART; SM00643; C345C; 1.
DR   SUPFAM; SSF47686; SSF47686; 1.
DR   SUPFAM; SSF48239; SSF48239; 1.
DR   SUPFAM; SSF49410; SSF49410; 1.
DR   SUPFAM; SSF50242; SSF50242; 1.
DR   PROSITE; PS01177; ANAPHYLATOXIN_1; 1.
DR   PROSITE; PS01178; ANAPHYLATOXIN_2; 1.
DR   PROSITE; PS50189; NTR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cleavage on pair of basic residues;
KW   Complement alternate pathway; Complement pathway; Complete proteome;
KW   Cytolysis; Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Immunity; Inflammatory response; Innate immunity;
KW   Membrane attack complex; Polymorphism; Reference proteome; Secreted;
KW   Signal.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19    673       Complement C5 beta chain.
FT                                /FTId=PRO_0000005985.
FT   PROPEP      674    677       {ECO:0000269|PubMed:690134}.
FT                                /FTId=PRO_0000005986.
FT   CHAIN       678   1676       Complement C5 alpha chain.
FT                                /FTId=PRO_0000005987.
FT   CHAIN       678    751       C5a anaphylatoxin.
FT                                /FTId=PRO_0000005988.
FT   CHAIN       752   1676       Complement C5 alpha' chain.
FT                                /FTId=PRO_0000005989.
FT   DOMAIN      698    732       Anaphylatoxin-like. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00022}.
FT   DOMAIN     1532   1676       NTR. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00295}.
FT   REGION      692    721       Involved in C5AR1 binding.
FT                                {ECO:0000269|PubMed:9553099}.
FT   CARBOHYD    741    741       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:18536718}.
FT   CARBOHYD    911    911       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:18536718,
FT                                ECO:0000269|PubMed:21217642}.
FT   CARBOHYD   1115   1115       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1630   1630       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952}.
FT   DISULFID    567    810
FT   DISULFID    634    669
FT   DISULFID    698    724
FT   DISULFID    699    731
FT   DISULFID    711    732
FT   DISULFID    856    883
FT   DISULFID    866   1527
FT   DISULFID   1101   1159
FT   DISULFID   1375   1505
FT   DISULFID   1405   1474
FT   DISULFID   1520   1525
FT   DISULFID   1532   1606
FT   DISULFID   1553   1676
FT   DISULFID   1654   1657
FT   VARIANT     145    145       V -> I (in dbSNP:rs17216529).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_038735.
FT   VARIANT     354    354       L -> M (in dbSNP:rs34552775).
FT                                /FTId=VAR_048822.
FT   VARIANT     389    389       T -> I. {ECO:0000269|PubMed:15488949,
FT                                ECO:0000269|PubMed:1984448}.
FT                                /FTId=VAR_023946.
FT   VARIANT     449    449       R -> G (in dbSNP:rs2230213).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_038736.
FT   VARIANT     518    518       F -> S.
FT                                /FTId=VAR_001996.
FT   VARIANT     802    802       V -> I (in dbSNP:rs17611).
FT                                {ECO:0000269|PubMed:15488949,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:1984448,
FT                                ECO:0000269|PubMed:2579066,
FT                                ECO:0000269|PubMed:3365401,
FT                                ECO:0000269|Ref.2, ECO:0000269|Ref.3}.
FT                                /FTId=VAR_014574.
FT   VARIANT     885    885       R -> C (polymorphism associated with poor
FT                                response to eculizumab in PNH patients;
FT                                dbSNP:rs373359894).
FT                                {ECO:0000269|PubMed:24521109}.
FT                                /FTId=VAR_071067.
FT   VARIANT     885    885       R -> H (polymorphism associated with poor
FT                                response to eculizumab in PNH patients;
FT                                dbSNP:rs56040400).
FT                                {ECO:0000269|PubMed:24521109}.
FT                                /FTId=VAR_071068.
FT   VARIANT     928    928       R -> Q (in dbSNP:rs41309892).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_038737.
FT   VARIANT     933    933       G -> V (in dbSNP:rs41309902).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_038738.
FT   VARIANT     966    966       D -> Y (polymorphism; confirmed at
FT                                protein level; dbSNP:rs2230212).
FT                                {ECO:0000269|PubMed:22028381}.
FT                                /FTId=VAR_048823.
FT   VARIANT    1033   1033       I -> T (in dbSNP:rs41311881).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_038739.
FT   VARIANT    1037   1037       D -> N (in dbSNP:rs41311883).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_038740.
FT   VARIANT    1043   1043       Q -> K (in dbSNP:rs41311887).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_038741.
FT   VARIANT    1053   1053       M -> L (in dbSNP:rs17609).
FT                                /FTId=VAR_014575.
FT   VARIANT    1310   1310       S -> N (in dbSNP:rs17610).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_014576.
FT   VARIANT    1365   1365       V -> A (in dbSNP:rs16910245).
FT                                /FTId=VAR_048824.
FT   VARIANT    1437   1437       E -> D (in dbSNP:rs17612).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_014577.
FT   STRAND       22     26       {ECO:0000244|PDB:5B71}.
FT   STRAND       29     45       {ECO:0000244|PDB:5B71}.
FT   STRAND       50     58       {ECO:0000244|PDB:5B71}.
FT   TURN         59     61       {ECO:0000244|PDB:5B71}.
FT   STRAND       65     73       {ECO:0000244|PDB:5B71}.
FT   TURN         75     79       {ECO:0000244|PDB:5B71}.
FT   STRAND       80     87       {ECO:0000244|PDB:5B71}.
FT   HELIX        89     91       {ECO:0000244|PDB:5HCC}.
FT   STRAND       95     97       {ECO:0000244|PDB:5HCC}.
FT   STRAND      101    107       {ECO:0000244|PDB:5B71}.
FT   STRAND      112    120       {ECO:0000244|PDB:5B71}.
FT   STRAND      124    131       {ECO:0000244|PDB:5HCC}.
FT   STRAND      133    135       {ECO:0000244|PDB:5HCC}.
FT   STRAND      143    148       {ECO:0000244|PDB:5HCC}.
FT   STRAND      152    154       {ECO:0000244|PDB:5HCC}.
FT   STRAND      159    164       {ECO:0000244|PDB:5HCC}.
FT   STRAND      170    176       {ECO:0000244|PDB:5HCC}.
FT   STRAND      179    184       {ECO:0000244|PDB:5HCC}.
FT   STRAND      197    208       {ECO:0000244|PDB:5HCC}.
FT   STRAND      212    219       {ECO:0000244|PDB:5HCC}.
FT   STRAND      226    234       {ECO:0000244|PDB:5HCC}.
FT   STRAND      236    238       {ECO:0000244|PDB:5HCC}.
FT   TURN        241    244       {ECO:0000244|PDB:4A5W}.
FT   STRAND      246    254       {ECO:0000244|PDB:5HCC}.
FT   TURN        255    257       {ECO:0000244|PDB:5HCC}.
FT   STRAND      262    273       {ECO:0000244|PDB:5HCC}.
FT   STRAND      275    277       {ECO:0000244|PDB:5HCC}.
FT   STRAND      281    283       {ECO:0000244|PDB:5HCC}.
FT   STRAND      289    293       {ECO:0000244|PDB:5HCC}.
FT   STRAND      296    301       {ECO:0000244|PDB:5HCC}.
FT   HELIX       303    307       {ECO:0000244|PDB:5HCC}.
FT   TURN        308    310       {ECO:0000244|PDB:5HCC}.
FT   STRAND      314    318       {ECO:0000244|PDB:5HCC}.
FT   STRAND      322    331       {ECO:0000244|PDB:5HCC}.
FT   TURN        332    334       {ECO:0000244|PDB:5HCC}.
FT   STRAND      337    347       {ECO:0000244|PDB:5HCC}.
FT   STRAND      353    356       {ECO:0000244|PDB:5HCC}.
FT   STRAND      361    363       {ECO:0000244|PDB:5HCC}.
FT   STRAND      365    367       {ECO:0000244|PDB:3CU7}.
FT   STRAND      369    376       {ECO:0000244|PDB:5HCC}.
FT   STRAND      378    380       {ECO:0000244|PDB:4A5W}.
FT   STRAND      387    396       {ECO:0000244|PDB:5HCC}.
FT   STRAND      401    403       {ECO:0000244|PDB:5HCC}.
FT   STRAND      407    410       {ECO:0000244|PDB:5HCC}.
FT   TURN        413    415       {ECO:0000244|PDB:5HCC}.
FT   STRAND      416    422       {ECO:0000244|PDB:5HCC}.
FT   STRAND      428    437       {ECO:0000244|PDB:5HCC}.
FT   HELIX       444    446       {ECO:0000244|PDB:3CU7}.
FT   STRAND      449    456       {ECO:0000244|PDB:5HCC}.
FT   STRAND      464    468       {ECO:0000244|PDB:5HCC}.
FT   STRAND      472    476       {ECO:0000244|PDB:3CU7}.
FT   STRAND      480    492       {ECO:0000244|PDB:5HCC}.
FT   HELIX       493    495       {ECO:0000244|PDB:5HCC}.
FT   STRAND      498    505       {ECO:0000244|PDB:5HCC}.
FT   STRAND      508    516       {ECO:0000244|PDB:5HCC}.
FT   STRAND      519    522       {ECO:0000244|PDB:3CU7}.
FT   STRAND      524    529       {ECO:0000244|PDB:5HCC}.
FT   HELIX       532    534       {ECO:0000244|PDB:5HCC}.
FT   STRAND      536    546       {ECO:0000244|PDB:5HCC}.
FT   STRAND      548    550       {ECO:0000244|PDB:5HCC}.
FT   STRAND      553    563       {ECO:0000244|PDB:5HCC}.
FT   STRAND      571    577       {ECO:0000244|PDB:5HCC}.
FT   STRAND      580    582       {ECO:0000244|PDB:3CU7}.
FT   STRAND      587    606       {ECO:0000244|PDB:5HCC}.
FT   HELIX       607    610       {ECO:0000244|PDB:5HCC}.
FT   HELIX       614    616       {ECO:0000244|PDB:4A5W}.
FT   HELIX       623    627       {ECO:0000244|PDB:5HCC}.
FT   HELIX       628    630       {ECO:0000244|PDB:4A5W}.
FT   STRAND      635    637       {ECO:0000244|PDB:5HCC}.
FT   HELIX       642    648       {ECO:0000244|PDB:5HCC}.
FT   STRAND      651    657       {ECO:0000244|PDB:5HCC}.
FT   TURN        663    666       {ECO:0000244|PDB:5HCD}.
FT   HELIX       678    687       {ECO:0000244|PDB:4UU9}.
FT   TURN        689    692       {ECO:0000244|PDB:3HQB}.
FT   HELIX       693    703       {ECO:0000244|PDB:4UU9}.
FT   STRAND      707    709       {ECO:0000244|PDB:4UU9}.
FT   HELIX       711    715       {ECO:0000244|PDB:4UU9}.
FT   HELIX       722    740       {ECO:0000244|PDB:4UU9}.
FT   TURN        744    746       {ECO:0000244|PDB:5B4P}.
FT   STRAND      764    767       {ECO:0000244|PDB:5HCC}.
FT   STRAND      777    789       {ECO:0000244|PDB:5HCC}.
FT   STRAND      795    805       {ECO:0000244|PDB:5HCC}.
FT   STRAND      808    811       {ECO:0000244|PDB:5HCC}.
FT   STRAND      815    819       {ECO:0000244|PDB:5HCC}.
FT   STRAND      822    828       {ECO:0000244|PDB:5HCC}.
FT   STRAND      838    847       {ECO:0000244|PDB:5HCC}.
FT   STRAND      849    851       {ECO:0000244|PDB:5HCC}.
FT   STRAND      853    859       {ECO:0000244|PDB:5HCC}.
FT   STRAND      863    869       {ECO:0000244|PDB:5HCC}.
FT   STRAND      874    877       {ECO:0000244|PDB:4A5W}.
FT   STRAND      886    888       {ECO:0000244|PDB:5HCC}.
FT   STRAND      892    902       {ECO:0000244|PDB:5HCC}.
FT   STRAND      906    916       {ECO:0000244|PDB:5HCC}.
FT   STRAND      919    930       {ECO:0000244|PDB:5HCC}.
FT   STRAND      932    945       {ECO:0000244|PDB:5HCC}.
FT   STRAND      949    952       {ECO:0000244|PDB:5HCC}.
FT   STRAND      956    959       {ECO:0000244|PDB:5HCC}.
FT   STRAND      974    982       {ECO:0000244|PDB:5HCC}.
FT   HELIX       985    992       {ECO:0000244|PDB:5HCC}.
FT   STRAND      993    996       {ECO:0000244|PDB:3CU7}.
FT   TURN        999   1002       {ECO:0000244|PDB:5HCC}.
FT   HELIX      1008   1013       {ECO:0000244|PDB:5HCC}.
FT   HELIX      1016   1027       {ECO:0000244|PDB:5HCC}.
FT   HELIX      1031   1033       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1034   1036       {ECO:0000244|PDB:5HCC}.
FT   HELIX      1038   1054       {ECO:0000244|PDB:5HCC}.
FT   HELIX      1055   1059       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1066   1069       {ECO:0000244|PDB:5HCC}.
FT   HELIX      1076   1089       {ECO:0000244|PDB:5HCC}.
FT   TURN       1090   1092       {ECO:0000244|PDB:5HCC}.
FT   HELIX      1097   1110       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1121   1123       {ECO:0000244|PDB:5HCC}.
FT   HELIX      1133   1154       {ECO:0000244|PDB:5HCC}.
FT   HELIX      1155   1158       {ECO:0000244|PDB:5HCC}.
FT   HELIX      1162   1178       {ECO:0000244|PDB:5HCC}.
FT   HELIX      1185   1196       {ECO:0000244|PDB:5HCC}.
FT   HELIX      1203   1214       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1217   1219       {ECO:0000244|PDB:5HCC}.
FT   TURN       1220   1223       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1224   1227       {ECO:0000244|PDB:5HCC}.
FT   TURN       1233   1235       {ECO:0000244|PDB:5HCC}.
FT   HELIX      1245   1260       {ECO:0000244|PDB:5HCC}.
FT   HELIX      1264   1277       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1280   1282       {ECO:0000244|PDB:3CU7}.
FT   HELIX      1287   1303       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1310   1317       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1324   1332       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1338   1340       {ECO:0000244|PDB:4A5W}.
FT   STRAND     1342   1344       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1346   1350       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1357   1368       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1371   1373       {ECO:0000244|PDB:3CU7}.
FT   STRAND     1376   1384       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1401   1408       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1420   1427       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1432   1434       {ECO:0000244|PDB:5HCC}.
FT   HELIX      1436   1443       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1451   1456       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1459   1465       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1469   1471       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1473   1483       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1485   1487       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1491   1497       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1500   1509       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1522   1524       {ECO:0000244|PDB:5HCC}.
FT   TURN       1526   1529       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1530   1532       {ECO:0000244|PDB:5HCC}.
FT   HELIX      1547   1550       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1559   1571       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1574   1590       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1597   1605       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1616   1622       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1625   1629       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1632   1638       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1644   1647       {ECO:0000244|PDB:5HCC}.
FT   STRAND     1650   1652       {ECO:0000244|PDB:5HCC}.
FT   HELIX      1657   1672       {ECO:0000244|PDB:5HCC}.
SQ   SEQUENCE   1676 AA;  188305 MW;  A7589E352F74672A CRC64;
     MGLLGILCFL IFLGKTWGQE QTYVISAPKI FRVGASENIV IQVYGYTEAF DATISIKSYP
     DKKFSYSSGH VHLSSENKFQ NSAILTIQPK QLPGGQNPVS YVYLEVVSKH FSKSKRMPIT
     YDNGFLFIHT DKPVYTPDQS VKVRVYSLND DLKPAKRETV LTFIDPEGSE VDMVEEIDHI
     GIISFPDFKI PSNPRYGMWT IKAKYKEDFS TTGTAYFEVK EYVLPHFSVS IEPEYNFIGY
     KNFKNFEITI KARYFYNKVV TEADVYITFG IREDLKDDQK EMMQTAMQNT MLINGIAQVT
     FDSETAVKEL SYYSLEDLNN KYLYIAVTVI ESTGGFSEEA EIPGIKYVLS PYKLNLVATP
     LFLKPGIPYP IKVQVKDSLD QLVGGVPVTL NAQTIDVNQE TSDLDPSKSV TRVDDGVASF
     VLNLPSGVTV LEFNVKTDAP DLPEENQARE GYRAIAYSSL SQSYLYIDWT DNHKALLVGE
     HLNIIVTPKS PYIDKITHYN YLILSKGKII HFGTREKFSD ASYQSINIPV TQNMVPSSRL
     LVYYIVTGEQ TAELVSDSVW LNIEEKCGNQ LQVHLSPDAD AYSPGQTVSL NMATGMDSWV
     ALAAVDSAVY GVQRGAKKPL ERVFQFLEKS DLGCGAGGGL NNANVFHLAG LTFLTNANAD
     DSQENDEPCK EILRPRRTLQ KKIEEIAAKY KHSVVKKCCY DGACVNNDET CEQRAARISL
     GPRCIKAFTE CCVVASQLRA NISHKDMQLG RLHMKTLLPV SKPEIRSYFP ESWLWEVHLV
     PRRKQLQFAL PDSLTTWEIQ GVGISNTGIC VADTVKAKVF KDVFLEMNIP YSVVRGEQIQ
     LKGTVYNYRT SGMQFCVKMS AVEGICTSES PVIDHQGTKS SKCVRQKVEG SSSHLVTFTV
     LPLEIGLHNI NFSLETWFGK EILVKTLRVV PEGVKRESYS GVTLDPRGIY GTISRRKEFP
     YRIPLDLVPK TEIKRILSVK GLLVGEILSA VLSQEGINIL THLPKGSAEA ELMSVVPVFY
     VFHYLETGNH WNIFHSDPLI EKQKLKKKLK EGMLSIMSYR NADYSYSVWK GGSASTWLTA
     FALRVLGQVN KYVEQNQNSI CNSLLWLVEN YQLDNGSFKE NSQYQPIKLQ GTLPVEAREN
     SLYLTAFTVI GIRKAFDICP LVKIDTALIK ADNFLLENTL PAQSTFTLAI SAYALSLGDK
     THPQFRSIVS ALKREALVKG NPPIYRFWKD NLQHKDSSVP NTGTARMVET TAYALLTSLN
     LKDINYVNPV IKWLSEEQRY GGGFYSTQDT INAIEGLTEY SLLVKQLRLS MDIDVSYKHK
     GALHNYKMTD KNFLGRPVEV LLNDDLIVST GFGSGLATVH VTTVVHKTST SEEVCSFYLK
     IDTQDIEASH YRGYGNSDYK RIVACASYKP SREESSSGSS HAVMDISLPT GISANEEDLK
     ALVEGVDQLF TDYQIKDGHV ILQLNSIPSS DFLCVRFRIF ELFEVGFLSP ATFTVYEYHR
     PDKQCTMFYS TSNIKIQKVC EGAACKCVEA DCGQMQEELD LTISAETRKQ TACKPEIAYA
     YKVSITSITV ENVFVKYKAT LLDIYKTGEA VAEKDSEITF IKKVTCTNAE LVKGRQYLIM
     GKEALQIKYN FSFRYIYPLD SLTWIEYWPR DTTCSSCQAF LANLDEFAED IFLNGC
//
ID   CO9_HUMAN               Reviewed;         559 AA.
AC   P02748;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 2.
DT   20-JUN-2018, entry version 190.
DE   RecName: Full=Complement component C9;
DE   Contains:
DE     RecName: Full=Complement component C9a;
DE   Contains:
DE     RecName: Full=Complement component C9b;
DE   Flags: Precursor;
GN   Name=C9;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=4018030;
RA   Stanley K.K., Kocher H.-P., Luzio J.P., Jackson P., Tschopp J.;
RT   "The sequence and topology of human complement component C9.";
RL   EMBO J. 4:375-382(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2-559, AND PROTEIN SEQUENCE OF
RP   N-TERMINUS.
RX   PubMed=6095282; DOI=10.1073/pnas.81.23.7298;
RA   Discipio R.G., Gehring M.R., Podack E.R., Kan C.C., Hugli T.E.,
RA   Fey G.H.;
RT   "Nucleotide sequence of cDNA and derived amino acid sequence of human
RT   complement component C9.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:7298-7302(1984).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 62-159.
RX   PubMed=3219351; DOI=10.1021/bi00417a050;
RA   Marazziti D., Eggertsen G., Fey G.H., Stanley K.K.;
RT   "Relationships between the gene and protein structure in human
RT   complement component C9.";
RL   Biochemistry 27:6529-6534(1988).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 27-559, VARIANT C9D GLY-119,
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=9634479; DOI=10.1007/s002510050415;
RA   Witzel-Schloemp K., Hobart M.J., Fernie B.A., Orren A., Wuerzner R.,
RA   Rittner C., Kaufmann T., Schneider P.M.;
RT   "Heterogeneity in the genetic basis of human complement C9
RT   deficiency.";
RL   Immunogenetics 48:144-147(1998).
RN   [6]
RP   PARTIAL PROTEIN SEQUENCE, ELECTRON MICROSCOPY, FUNCTION, SUBCELLULAR
RP   LOCATION, PROTEOLYTIC CLEAVAGE, AND GLYCOSYLATION AT ASN-277 AND
RP   ASN-415.
RX   PubMed=4055801;
RA   DiScipio R.G., Hugli T.E.;
RT   "The architecture of complement component C9 and poly(C9).";
RL   J. Biol. Chem. 260:14802-14809(1985).
RN   [7]
RP   DISULFIDE BONDS.
RX   PubMed=8603752; DOI=10.1016/0014-5793(95)01541-8;
RA   Lengweiler S., Schaller J., Rickli E.E.;
RT   "Identification of disulfide bonds in the ninth component (C9) of
RT   human complement.";
RL   FEBS Lett. 380:8-12(1996).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=9212048; DOI=10.1203/00006450-199707000-00020;
RA   Lassiter H.A., Walz B.M., Wilson J.L., Jung E., Calisi C.R.,
RA   Goldsmith L.J., Wilson R.A., Morgan B.P., Feldhoff R.C.;
RT   "The administration of complement component C9 enhances the survival
RT   of neonatal rats with Escherichia coli sepsis.";
RL   Pediatr. Res. 42:128-136(1997).
RN   [9]
RP   GLYCOSYLATION AT TRP-48 AND TRP-51.
RX   PubMed=10551839; DOI=10.1074/jbc.274.46.32786;
RA   Hofsteenge J., Blommers M., Hess D., Furmanek A., Miroshnichenko O.;
RT   "The four terminal components of the complement system are C-
RT   mannosylated on multiple tryptophan residues.";
RL   J. Biol. Chem. 274:32786-32794(1999).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-415.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [11]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-277 AND ASN-415.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [12]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-415.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.M500324-MCP200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-277 AND ASN-415.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [14]
RP   GLYCOSYLATION AT ASN-415.
RX   PubMed=19139490; DOI=10.1074/mcp.M800504-MCP200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F.,
RA   Zheng Z.B., Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y.,
RA   Zhang Y.K., Deng Y.L., Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core
RT   fucosylated glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   3D-STRUCTURE MODELING OF MEMBRANE-SPANNING DOMAIN (MSB).
RX   PubMed=2395434; DOI=10.1016/0161-5890(90)90001-G;
RA   Peitsch M.C., Amiguet P., Guy R., Brunner J., Maizel J.V. Jr.,
RA   Tschopp J.;
RT   "Localization and molecular modelling of the membrane-inserted domain
RT   of the ninth component of human complement and perforin.";
RL   Mol. Immunol. 27:589-602(1990).
RN   [17]
RP   ELECTRON MICROSCOPY, SUBUNIT, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=22832194; DOI=10.1016/j.celrep.2012.02.003;
RA   Hadders M.A., Bubeck D., Roversi P., Hakobyan S., Forneris F.,
RA   Morgan B.P., Pangburn M.K., Llorca O., Lea S.M., Gros P.;
RT   "Assembly and regulation of the membrane attack complex based on
RT   structures of C5b6 and sC5b9.";
RL   Cell Rep. 1:200-207(2012).
RN   [18]
RP   STRUCTURE BY ELECTRON MICROSCOPY (6.70 ANGSTROMS) OF 39-544, FUNCTION,
RP   SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=26841934; DOI=10.1038/ncomms10588;
RA   Dudkina N.V., Spicer B.A., Reboul C.F., Conroy P.J., Lukoyanova N.,
RA   Elmlund H., Law R.H., Ekkel S.M., Kondos S.C., Goode R.J., Ramm G.,
RA   Whisstock J.C., Saibil H.R., Dunstone M.A.;
RT   "Structure of the poly-C9 component of the complement membrane attack
RT   complex.";
RL   Nat. Commun. 7:10588-10588(2016).
RN   [19]
RP   VARIANT ARMD15 SER-167.
RX   PubMed=24036952; DOI=10.1038/ng.2741;
RA   Seddon J.M., Yu Y., Miller E.C., Reynolds R., Tan P.L.,
RA   Gowrisankar S., Goldstein J.I., Triebwasser M., Anderson H.E.,
RA   Zerbib J., Kavanagh D., Souied E., Katsanis N., Daly M.J.,
RA   Atkinson J.P., Raychaudhuri S.;
RT   "Rare variants in CFI, C3 and C9 are associated with high risk of
RT   advanced age-related macular degeneration.";
RL   Nat. Genet. 45:1366-1370(2013).
CC   -!- FUNCTION: Constituent of the membrane attack complex (MAC) that
CC       plays a key role in the innate and adaptive immune response by
CC       forming pores in the plasma membrane of target cells
CC       (PubMed:9634479, PubMed:9212048, PubMed:26841934). C9 is the pore-
CC       forming subunit of the MAC (PubMed:4055801, PubMed:26841934).
CC       {ECO:0000269|PubMed:26841934, ECO:0000269|PubMed:4055801,
CC       ECO:0000269|PubMed:9212048, ECO:0000269|PubMed:9634479}.
CC   -!- SUBUNIT: Component of the membrane attack complex (MAC). MAC
CC       assembly is initiated by proteolytic cleavage of C5 into C5a and
CC       C5b. C5b binds sequentially C6, C7, C8 and multiple copies of the
CC       pore-forming subunit C9 (PubMed:22832194). About 20 C9 chains
CC       oligomerize to give rise to a huge beta-barrel that forms a 100
CC       Angstrom diameter pore in target membranes (PubMed:26841934).
CC       {ECO:0000269|PubMed:22832194, ECO:0000269|PubMed:26841934}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:22832194,
CC       ECO:0000269|PubMed:26841934, ECO:0000269|PubMed:9212048,
CC       ECO:0000269|PubMed:9634479}. Target cell membrane
CC       {ECO:0000269|PubMed:26841934, ECO:0000269|PubMed:9212048}; Multi-
CC       pass membrane protein {ECO:0000269|PubMed:26841934}. Note=Secreted
CC       as soluble monomer. Oligomerizes at target membranes, forming a
CC       pre-pore. A conformation change then leads to the formation of a
CC       100 Angstrom diameter pore. {ECO:0000269|PubMed:26841934,
CC       ECO:0000269|PubMed:4055801, ECO:0000269|PubMed:9634479}.
CC   -!- TISSUE SPECIFICITY: Plasma (at protein level).
CC       {ECO:0000269|PubMed:22832194, ECO:0000269|PubMed:26841934,
CC       ECO:0000269|PubMed:9212048, ECO:0000269|PubMed:9634479}.
CC   -!- PTM: Thrombin cleaves factor C9 to produce C9a and C9b.
CC       {ECO:0000269|PubMed:4055801}.
CC   -!- PTM: Phosphorylation sites are present in the extracellular
CC       medium.
CC   -!- DISEASE: Complement component 9 deficiency (C9D) [MIM:613825]: A
CC       rare defect of the complement classical pathway associated with
CC       susceptibility to severe recurrent infections predominantly by
CC       Neisseria gonorrhoeae or Neisseria meningitidis. Some patients may
CC       develop dermatomyositis. {ECO:0000269|PubMed:9634479}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Macular degeneration, age-related, 15 (ARMD15)
CC       [MIM:615591]: A form of age-related macular degeneration, a
CC       multifactorial eye disease and the most common cause of
CC       irreversible vision loss in the developed world. In most patients,
CC       the disease is manifest as ophthalmoscopically visible yellowish
CC       accumulations of protein and lipid that lie beneath the retinal
CC       pigment epithelium and within an elastin-containing structure
CC       known as Bruch membrane. {ECO:0000269|PubMed:24036952}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the complement C6/C7/C8/C9 family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=C9base; Note=C9 mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/C9base/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; X02176; CAA26117.1; -; mRNA.
DR   EMBL; BC020721; AAH20721.1; -; mRNA.
DR   EMBL; K02766; AAA51889.1; -; mRNA.
DR   EMBL; J02833; AAA51890.1; -; Genomic_DNA.
DR   EMBL; Y08545; CAA69849.1; -; Genomic_DNA.
DR   EMBL; Y08546; CAA69849.1; JOINED; Genomic_DNA.
DR   EMBL; Y08547; CAA69849.1; JOINED; Genomic_DNA.
DR   EMBL; Y08548; CAA69849.1; JOINED; Genomic_DNA.
DR   EMBL; Y08549; CAA69849.1; JOINED; Genomic_DNA.
DR   EMBL; Y08550; CAA69849.1; JOINED; Genomic_DNA.
DR   EMBL; Y08551; CAA69849.1; JOINED; Genomic_DNA.
DR   EMBL; Y08552; CAA69849.1; JOINED; Genomic_DNA.
DR   EMBL; Y08553; CAA69849.1; JOINED; Genomic_DNA.
DR   EMBL; Y08554; CAA69849.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS3929.1; -.
DR   PIR; A59363; C9HU.
DR   RefSeq; NP_001728.1; NM_001737.4.
DR   UniGene; Hs.654443; -.
DR   PDB; 5FMW; EM; 6.70 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V=39-544.
DR   PDBsum; 5FMW; -.
DR   ProteinModelPortal; P02748; -.
DR   SMR; P02748; -.
DR   BioGrid; 107196; 6.
DR   DIP; DIP-1124N; -.
DR   ELM; P02748; -.
DR   STRING; 9606.ENSP00000263408; -.
DR   iPTMnet; P02748; -.
DR   PhosphoSitePlus; P02748; -.
DR   BioMuta; C9; -.
DR   DMDM; 1352108; -.
DR   MaxQB; P02748; -.
DR   PaxDb; P02748; -.
DR   PeptideAtlas; P02748; -.
DR   PRIDE; P02748; -.
DR   ProteomicsDB; 51564; -.
DR   DNASU; 735; -.
DR   Ensembl; ENST00000263408; ENSP00000263408; ENSG00000113600.
DR   GeneID; 735; -.
DR   KEGG; hsa:735; -.
DR   UCSC; uc003jlv.5; human.
DR   CTD; 735; -.
DR   DisGeNET; 735; -.
DR   EuPathDB; HostDB:ENSG00000113600.10; -.
DR   GeneCards; C9; -.
DR   HGNC; HGNC:1358; C9.
DR   HPA; CAB002151; -.
DR   HPA; HPA029577; -.
DR   MalaCards; C9; -.
DR   MIM; 120940; gene.
DR   MIM; 613825; phenotype.
DR   MIM; 615591; phenotype.
DR   neXtProt; NX_P02748; -.
DR   OpenTargets; ENSG00000113600; -.
DR   Orphanet; 279; Age-related macular degeneration.
DR   Orphanet; 169150; Immunodeficiency due to a late component of complements deficiency.
DR   PharmGKB; PA25968; -.
DR   eggNOG; ENOG410IH3C; Eukaryota.
DR   eggNOG; ENOG410XT9A; LUCA.
DR   GeneTree; ENSGT00550000074478; -.
DR   HOGENOM; HOG000111869; -.
DR   HOVERGEN; HBG106792; -.
DR   InParanoid; P02748; -.
DR   KO; K04000; -.
DR   OMA; GINILGM; -.
DR   OrthoDB; EOG091G07LK; -.
DR   PhylomeDB; P02748; -.
DR   TreeFam; TF330498; -.
DR   Reactome; R-HSA-166665; Terminal pathway of complement.
DR   Reactome; R-HSA-977606; Regulation of Complement cascade.
DR   ChiTaRS; C9; human.
DR   GenomeRNAi; 735; -.
DR   PRO; PR:P02748; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000113600; -.
DR   CleanEx; HS_C9; -.
DR   Genevisible; P02748; HS.
DR   GO; GO:0072562; C:blood microparticle; HDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005579; C:membrane attack complex; IDA:UniProtKB.
DR   GO; GO:0044218; C:other organism cell membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0001906; P:cell killing; IDA:UniProtKB.
DR   GO; GO:0006957; P:complement activation, alternative pathway; IEA:UniProtKB-KW.
DR   GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW.
DR   GO; GO:0019836; P:hemolysis by symbiont of host erythrocytes; TAS:ProtInc.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB.
DR   GO; GO:0030449; P:regulation of complement activation; TAS:Reactome.
DR   CDD; cd00112; LDLa; 1.
DR   Gene3D; 2.20.100.10; -; 1.
DR   InterPro; IPR037567; Complement_C9.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR036055; LDL_receptor-like_sf.
DR   InterPro; IPR023415; LDLR_class-A_CS.
DR   InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR   InterPro; IPR001862; MAC_perforin.
DR   InterPro; IPR020864; MACPF.
DR   InterPro; IPR020863; MACPF_CS.
DR   InterPro; IPR000884; TSP1_rpt.
DR   InterPro; IPR036383; TSP1_rpt_sf.
DR   PANTHER; PTHR19325:SF362; PTHR19325:SF362; 1.
DR   Pfam; PF00057; Ldl_recept_a; 1.
DR   Pfam; PF01823; MACPF; 1.
DR   Pfam; PF00090; TSP_1; 1.
DR   PRINTS; PR00764; COMPLEMENTC9.
DR   SMART; SM00192; LDLa; 1.
DR   SMART; SM00457; MACPF; 1.
DR   SMART; SM00209; TSP1; 1.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   SUPFAM; SSF57424; SSF57424; 1.
DR   SUPFAM; SSF82895; SSF82895; 1.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS01209; LDLRA_1; 1.
DR   PROSITE; PS50068; LDLRA_2; 1.
DR   PROSITE; PS00279; MACPF_1; 1.
DR   PROSITE; PS51412; MACPF_2; 1.
DR   PROSITE; PS50092; TSP1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Age-related macular degeneration;
KW   Complement alternate pathway; Complement pathway; Complete proteome;
KW   Cytolysis; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; EGF-like domain; Glycoprotein; Immunity;
KW   Innate immunity; Membrane; Membrane attack complex; Phosphoprotein;
KW   Polymorphism; Reference proteome; Secreted; Signal;
KW   Target cell membrane; Target membrane; Transmembrane;
KW   Transmembrane beta strand.
FT   SIGNAL        1     21       {ECO:0000269|PubMed:6095282}.
FT   CHAIN        22    559       Complement component C9.
FT                                /FTId=PRO_0000023602.
FT   CHAIN        22    265       Complement component C9a.
FT                                /FTId=PRO_0000023603.
FT   CHAIN       266    559       Complement component C9b.
FT                                /FTId=PRO_0000023604.
FT   TRANSMEM    314    330       Beta stranded. {ECO:0000255}.
FT   TRANSMEM    335    354       Beta stranded. {ECO:0000255}.
FT   DOMAIN       42     95       TSP type-1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN       99    136       LDL-receptor class A.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      138    509       MACPF. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00745}.
FT   DOMAIN      510    540       EGF-like.
FT   SITE        265    266       Cleavage; by thrombin.
FT   CARBOHYD     48     48       C-linked (Man) tryptophan.
FT                                {ECO:0000269|PubMed:10551839}.
FT   CARBOHYD     51     51       C-linked (Man) tryptophan; partial.
FT                                {ECO:0000269|PubMed:10551839}.
FT   CARBOHYD    277    277       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:4055801}.
FT   CARBOHYD    415    415       N-linked (GlcNAc...) (complex)
FT                                asparagine. {ECO:0000269|PubMed:14760718,
FT                                ECO:0000269|PubMed:16263699,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19139490,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:4055801}.
FT   DISULFID     43     78       {ECO:0000269|PubMed:8603752}.
FT   DISULFID     54     57       {ECO:0000269|PubMed:8603752}.
FT   DISULFID     88     94       {ECO:0000269|PubMed:8603752}.
FT   DISULFID    101    112       {ECO:0000269|PubMed:8603752}.
FT   DISULFID    107    125       {ECO:0000269|PubMed:8603752}.
FT   DISULFID    119    134       {ECO:0000269|PubMed:8603752}.
FT   DISULFID    142    181       {ECO:0000269|PubMed:8603752}.
FT   DISULFID    254    255       {ECO:0000269|PubMed:8603752}.
FT   DISULFID    380    405       {ECO:0000269|PubMed:8603752}.
FT   DISULFID    510    526       {ECO:0000269|PubMed:8603752}.
FT   DISULFID    513    528       {ECO:0000269|PubMed:8603752}.
FT   DISULFID    530    539       {ECO:0000269|PubMed:8603752}.
FT   VARIANT       5      5       R -> W (in dbSNP:rs700233).
FT                                /FTId=VAR_022024.
FT   VARIANT     119    119       C -> G (in C9D; dbSNP:rs121909593).
FT                                {ECO:0000269|PubMed:9634479}.
FT                                /FTId=VAR_012648.
FT   VARIANT     127    127       D -> Y (in dbSNP:rs696763).
FT                                /FTId=VAR_050481.
FT   VARIANT     167    167       P -> S (in ARMD15; dbSNP:rs34882957).
FT                                {ECO:0000269|PubMed:24036952}.
FT                                /FTId=VAR_070940.
FT   VARIANT     203    203       I -> V (in dbSNP:rs13361416).
FT                                /FTId=VAR_027651.
FT   VARIANT     279    279       T -> S (in dbSNP:rs34625111).
FT                                /FTId=VAR_033802.
FT   VARIANT     427    427       S -> T (in dbSNP:rs34421659).
FT                                /FTId=VAR_061503.
FT   CONFLICT     43     43       C -> R (in Ref. 3; AAA51889).
FT                                {ECO:0000305}.
FT   CONFLICT    314    314       Missing (in Ref. 3; AAA51889).
FT                                {ECO:0000305}.
FT   CONFLICT    417    417       T -> P (in Ref. 3; AAA51889).
FT                                {ECO:0000305}.
SQ   SEQUENCE   559 AA;  63173 MW;  7403F6AD77B3ECE1 CRC64;
     MSACRSFAVA ICILEISILT AQYTTSYDPE LTESSGSASH IDCRMSPWSE WSQCDPCLRQ
     MFRSRSIEVF GQFNGKRCTD AVGDRRQCVP TEPCEDAEDD CGNDFQCSTG RCIKMRLRCN
     GDNDCGDFSD EDDCESEPRP PCRDRVVEES ELARTAGYGI NILGMDPLST PFDNEFYNGL
     CNRDRDGNTL TYYRRPWNVA SLIYETKGEK NFRTEHYEEQ IEAFKSIIQE KTSNFNAAIS
     LKFTPTETNK AEQCCEETAS SISLHGKGSF RFSYSKNETY QLFLSYSSKK EKMFLHVKGE
     IHLGRFVMRN RDVVLTTTFV DDIKALPTTY EKGEYFAFLE TYGTHYSSSG SLGGLYELIY
     VLDKASMKRK GVELKDIKRC LGYHLDVSLA FSEISVGAEF NKDDCVKRGE GRAVNITSEN
     LIDDVVSLIR GGTRKYAFEL KEKLLRGTVI DVTDFVNWAS SINDAPVLIS QKLSPIYNLV
     PVKMKNAHLK KQNLERAIED YINEFSVRKC HTCQNGGTVI LMDGKCLCAC PFKFEGIACE
     ISKQKISEGL PALEFPNEK
//
ID   CO9_ONCMY               Reviewed;         574 AA.
AC   P06682;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1991, sequence version 2.
DT   23-MAY-2018, entry version 109.
DE   RecName: Full=Complement component C9;
DE   Flags: Fragment;
GN   Name=c9;
OS   Oncorhynchus mykiss (Rainbow trout) (Salmo gairdneri).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Actinopterygii; Neopterygii; Teleostei; Protacanthopterygii;
OC   Salmoniformes; Salmonidae; Salmoninae; Oncorhynchus.
OX   NCBI_TaxID=8022;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2443347;
RA   Stanley K.K., Herz J.;
RT   "Topological mapping of complement component C9 by recombinant DNA
RT   techniques suggests a novel mechanism for its insertion into target
RT   membranes.";
RL   EMBO J. 6:1951-1957(1987).
RN   [2]
RP   SEQUENCE REVISION.
RX   PubMed=2808363;
RA   Haefliger J.-A., Tschopp J., Vial N., Jenne D.E.;
RT   "Complete primary structure and functional characterization of the
RT   sixth component of the human complement system. Identification of the
RT   C5b-binding domain in complement C6.";
RL   J. Biol. Chem. 264:18041-18051(1989).
CC   -!- FUNCTION: Constituent of the membrane attack complex (MAC) that
CC       plays a key role in the innate and adaptive immune response by
CC       forming pores in the plasma membrane of target cells. C9 is the
CC       pore-forming subunit of the MAC. {ECO:0000250|UniProtKB:P02748}.
CC   -!- SUBUNIT: Component of the membrane attack complex (MAC). About 20
CC       C9 chains oligomerize to give rise to a huge beta-barrel that
CC       forms a 100 Angstrom diameter pore in target membranes.
CC       {ECO:0000250|UniProtKB:P02748}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000250|UniProtKB:P02748}.
CC       Target cell membrane {ECO:0000250|UniProtKB:P02748}; Multi-pass
CC       membrane protein {ECO:0000250|UniProtKB:P02748}. Note=Secreted as
CC       soluble monomer. Oligomerizes at target membranes, forming a pre-
CC       pore. A conformation change then leads to the formation of a 100
CC       Angstrom diameter pore. {ECO:0000250|UniProtKB:P02748}.
CC   -!- SIMILARITY: Belongs to the complement C6/C7/C8/C9 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; X05474; CAA29037.1; ALT_SEQ; mRNA.
DR   PIR; B29677; B29677.
DR   UniGene; Omy.11483; -.
DR   ProteinModelPortal; P06682; -.
DR   SMR; P06682; -.
DR   HOVERGEN; HBG106792; -.
DR   GO; GO:0005615; C:extracellular space; ISS:UniProtKB.
DR   GO; GO:0005579; C:membrane attack complex; ISS:UniProtKB.
DR   GO; GO:0044218; C:other organism cell membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0001906; P:cell killing; ISS:UniProtKB.
DR   GO; GO:0006957; P:complement activation, alternative pathway; IEA:UniProtKB-KW.
DR   GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW.
DR   GO; GO:0019835; P:cytolysis; IEA:UniProtKB-KW.
DR   GO; GO:0051260; P:protein homooligomerization; ISS:UniProtKB.
DR   CDD; cd00112; LDLa; 1.
DR   Gene3D; 2.20.100.10; -; 1.
DR   InterPro; IPR037567; Complement_C9.
DR   InterPro; IPR036055; LDL_receptor-like_sf.
DR   InterPro; IPR023415; LDLR_class-A_CS.
DR   InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR   InterPro; IPR001862; MAC_perforin.
DR   InterPro; IPR020864; MACPF.
DR   InterPro; IPR020863; MACPF_CS.
DR   InterPro; IPR000884; TSP1_rpt.
DR   InterPro; IPR036383; TSP1_rpt_sf.
DR   PANTHER; PTHR19325:SF362; PTHR19325:SF362; 1.
DR   Pfam; PF00057; Ldl_recept_a; 1.
DR   Pfam; PF01823; MACPF; 1.
DR   PRINTS; PR00764; COMPLEMENTC9.
DR   SMART; SM00192; LDLa; 1.
DR   SMART; SM00457; MACPF; 1.
DR   SMART; SM00209; TSP1; 2.
DR   SUPFAM; SSF57424; SSF57424; 1.
DR   SUPFAM; SSF82895; SSF82895; 2.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01209; LDLRA_1; 1.
DR   PROSITE; PS50068; LDLRA_2; 1.
DR   PROSITE; PS00279; MACPF_1; 1.
DR   PROSITE; PS51412; MACPF_2; 1.
DR   PROSITE; PS50092; TSP1; 2.
PE   2: Evidence at transcript level;
KW   Complement alternate pathway; Complement pathway; Cytolysis;
KW   Disulfide bond; EGF-like domain; Glycoprotein; Immunity;
KW   Innate immunity; Membrane; Membrane attack complex; Repeat; Secreted;
KW   Target cell membrane; Target membrane; Transmembrane;
KW   Transmembrane beta strand.
FT   CHAIN        <1    574       Complement component C9.
FT                                /FTId=PRO_0000162510.
FT   TRANSMEM    284    300       Beta stranded. {ECO:0000255}.
FT   TRANSMEM    305    324       Beta stranded. {ECO:0000255}.
FT   DOMAIN       18     72       TSP type-1 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN       77    117       LDL-receptor class A.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      115    480       MACPF. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00745}.
FT   DOMAIN      481    511       EGF-like.
FT   DOMAIN      531    572       TSP type-1 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   CARBOHYD      3      3       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    231    231       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    261    261       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    533    533       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     19     54       {ECO:0000250}.
FT   DISULFID     30     33       {ECO:0000250}.
FT   DISULFID     65     71       {ECO:0000250}.
FT   DISULFID     79     91       {ECO:0000250}.
FT   DISULFID     86    104       {ECO:0000250}.
FT   DISULFID     98    112       {ECO:0000250}.
FT   DISULFID    119    158       {ECO:0000250}.
FT   DISULFID    350    376       {ECO:0000250}.
FT   DISULFID    481    497       {ECO:0000250}.
FT   DISULFID    484    499       {ECO:0000250}.
FT   DISULFID    501    510       {ECO:0000250}.
FT   NON_TER       1      1
SQ   SEQUENCE   574 AA;  64033 MW;  CB516A9F76824D59 CRC64;
     QANGTLGRSR WLPLDPVDCV WSRWSEWTPC NSCTKIRHRS RSVEVFGQFG GKPCQGQPIG
     EQQRCTSDAV CEQALPSECS SIEFTCESGA CIKLRLSCNG DYDCEDGSDE DCEPVRKPCG
     TKLYDTNEQG RTAGYGINIL GMEPRINPFN NDYFNGMCNK VKNINNNEYN RLPWNVGLLN
     YETIAEETVS KEIYEDTYTL LRELMTETKL TVSAGLNLKF TPTEKSMAKS NTTVSGGVGL
     DAEYDRTQMI KEVSEYTTIK NKSFMRVNGR VQLSTYRMRS RDLQVAGEFL EHVKSLPLEY
     EKGQYFSFLE DYGTHYTRNG KSGGEHQLVY VLNQDTIKDK KLTERKLQDC IKVGISANFD
     TNIGIGGDAH IRPGHCKDTV NKNTAEKEGK ALVDKVITVV RGGTLEAAVA MRTQITKEGL
     MDVKTYQNWA RTVGDAPALL SSEPEPIQTL IPLSMPDANT RRLNMQRATQ EYEAEYSVCK
     CKPCHNGGSL ALLDGKCLCL CLPQFEGLAC QDAKADNNKN TKTPVRVFLE KGNWSCWAAW
     SGCSGGKRIR TRSCNTQGLS DATCRGDIVT EDYC
//
ID   CO8A_HUMAN              Reviewed;         584 AA.
AC   P07357; A2RUI4; A2RUI5; Q13668; Q9H130;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1995, sequence version 2.
DT   18-JUL-2018, entry version 194.
DE   RecName: Full=Complement component C8 alpha chain;
DE   AltName: Full=Complement component 8 subunit alpha;
DE   Flags: Precursor;
GN   Name=C8A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Liver;
RX   PubMed=2820471; DOI=10.1021/bi00386a046;
RA   Rao A.G., Howard O.M.Z., Ng S.C., Whitehead A.S., Colten H.R.,
RA   Sodetz J.M.;
RT   "Complementary DNA and derived amino acid sequence of the alpha
RT   subunit of human complement protein C8: evidence for the existence of
RT   a separate alpha subunit messenger RNA.";
RL   Biochemistry 26:3556-3564(1987).
RN   [2]
RP   SEQUENCE REVISION TO 467-479.
RA   Sodetz J.M.;
RL   Submitted (FEB-1993) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=7759071; DOI=10.1007/BF00223862;
RA   Michelotti G.A., Snider J.V., Sodetz J.M.;
RT   "Genomic organization of human complement protein C8 alpha and further
RT   examination of its linkage to C8 beta.";
RL   Hum. Genet. 95:513-518(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LYS-93.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PARTIAL PROTEIN SEQUENCE, FUNCTION, AND SUBUNIT.
RX   PubMed=7440581;
RA   Steckel E.W., York R.G., Monahan J.B., Sodetz J.M.;
RT   "The eighth component of human complement. Purification and
RT   physicochemical characterization of its unusual subunit structure.";
RL   J. Biol. Chem. 255:11997-12005(1980).
RN   [7]
RP   GLYCOSYLATION AT TRP-44; TRP-542; TRP-545 AND TRP-548.
RX   PubMed=10551839; DOI=10.1074/jbc.274.46.32786;
RA   Hofsteenge J., Blommers M., Hess D., Furmanek A., Miroshnichenko O.;
RT   "The four terminal components of the complement system are C-
RT   mannosylated on multiple tryptophan residues.";
RL   J. Biol. Chem. 274:32786-32794(1999).
RN   [8]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-437.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [9]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-437.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 133-492, AND FUNCTION.
RX   PubMed=17872444; DOI=10.1126/science.1147103;
RA   Hadders M.A., Beringer D.X., Gros P.;
RT   "Structure of C8alpha-MACPF reveals mechanism of membrane attack in
RT   complement immune defense.";
RL   Science 317:1552-1554(2007).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 133-492 IN COMPLEX WITH C8G,
RP   AND INTERCHAIN DISULFIDE BOND.
RX   PubMed=18440555; DOI=10.1016/j.jmb.2008.03.061;
RA   Slade D.J., Lovelace L.L., Chruszcz M., Minor W., Lebioda L.,
RA   Sodetz J.M.;
RT   "Crystal structure of the MACPF domain of human complement protein C8
RT   alpha in complex with the C8 gamma subunit.";
RL   J. Mol. Biol. 379:331-342(2008).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.81 ANGSTROMS) OF 188-198 IN COMPLEX WITH C8G.
RX   PubMed=17692377; DOI=10.1016/j.molimm.2007.06.359;
RA   Lovelace L.L., Chiswell B., Slade D.J., Sodetz J.M., Lebioda L.;
RT   "Crystal structure of complement protein C8gamma in complex with a
RT   peptide containing the C8gamma binding site on C8alpha: implications
RT   for C8gamma ligand binding.";
RL   Mol. Immunol. 45:750-756(2008).
RN   [14]
RP   VARIANT C8A*B LYS-93.
RX   PubMed=7649542; DOI=10.1007/BF00210407;
RA   Zhang L., Rittner C., Sodetz J.M., Schneider P.M., Kaufmann T.;
RT   "The eighth component of human complement: molecular basis of C8A
RT   (C81) polymorphism.";
RL   Hum. Genet. 96:281-284(1995).
CC   -!- FUNCTION: Constituent of the membrane attack complex (MAC) that
CC       plays a key role in the innate and adaptive immune response by
CC       forming pores in the plasma membrane of target cells. C8A inserts
CC       into the target membrane, but does not form pores by itself.
CC       {ECO:0000269|PubMed:17872444, ECO:0000269|PubMed:7440581}.
CC   -!- SUBUNIT: Heterotrimer of 3 chains: alpha, beta and gamma. The
CC       alpha and gamma chains are disulfide bonded. Component of the
CC       membrane attack complex (MAC). MAC assembly is initiated by
CC       proteolytic cleavage of C5 into C5a and C5b. C5b sequentially
CC       binds C6, C7, C8 and multiple copies of the pore-forming subunit
CC       C9. {ECO:0000269|PubMed:17692377, ECO:0000269|PubMed:18440555,
CC       ECO:0000269|PubMed:7440581}.
CC   -!- SUBCELLULAR LOCATION: Secreted. Cell membrane; Multi-pass membrane
CC       protein. Note=Secreted as soluble protein. Inserts into the cell
CC       membrane of target cells.
CC   -!- DISEASE: Complement component 8 deficiency, 1 (C8D1) [MIM:613790]:
CC       A rare defect of the complement classical pathway associated with
CC       susceptibility to severe recurrent infections, predominantly by
CC       Neisseria gonorrhoeae or Neisseria meningitidis. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the complement C6/C7/C8/C9 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; M16974; AAA52200.1; -; mRNA.
DR   EMBL; U08006; AAA82124.1; -; Genomic_DNA.
DR   EMBL; U07996; AAA82124.1; JOINED; Genomic_DNA.
DR   EMBL; U07997; AAA82124.1; JOINED; Genomic_DNA.
DR   EMBL; U07998; AAA82124.1; JOINED; Genomic_DNA.
DR   EMBL; U07999; AAA82124.1; JOINED; Genomic_DNA.
DR   EMBL; U08000; AAA82124.1; JOINED; Genomic_DNA.
DR   EMBL; U08001; AAA82124.1; JOINED; Genomic_DNA.
DR   EMBL; U08002; AAA82124.1; JOINED; Genomic_DNA.
DR   EMBL; U08003; AAA82124.1; JOINED; Genomic_DNA.
DR   EMBL; U08004; AAA82124.1; JOINED; Genomic_DNA.
DR   EMBL; U08005; AAA82124.1; JOINED; Genomic_DNA.
DR   EMBL; AL121998; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC132911; AAI32912.1; -; mRNA.
DR   EMBL; BC132913; AAI32914.1; -; mRNA.
DR   CCDS; CCDS606.1; -.
DR   PIR; I37213; C8HUA.
DR   RefSeq; NP_000553.1; NM_000562.2.
DR   UniGene; Hs.93210; -.
DR   PDB; 2QOS; X-ray; 1.81 A; A=188-198.
DR   PDB; 2QQH; X-ray; 2.50 A; A=133-366, A=410-492.
DR   PDB; 2RD7; X-ray; 2.15 A; A=133-492.
DR   PDB; 3OJY; X-ray; 2.51 A; A=31-584.
DR   PDBsum; 2QOS; -.
DR   PDBsum; 2QQH; -.
DR   PDBsum; 2RD7; -.
DR   PDBsum; 3OJY; -.
DR   ProteinModelPortal; P07357; -.
DR   SMR; P07357; -.
DR   BioGrid; 107192; 13.
DR   DIP; DIP-1125N; -.
DR   IntAct; P07357; 2.
DR   STRING; 9606.ENSP00000354458; -.
DR   TCDB; 1.C.39.3.1; the membrane attack complex/perforin (macpf) family.
DR   iPTMnet; P07357; -.
DR   PhosphoSitePlus; P07357; -.
DR   BioMuta; C8A; -.
DR   DMDM; 729167; -.
DR   MaxQB; P07357; -.
DR   PaxDb; P07357; -.
DR   PeptideAtlas; P07357; -.
DR   PRIDE; P07357; -.
DR   ProteomicsDB; 51997; -.
DR   DNASU; 731; -.
DR   Ensembl; ENST00000361249; ENSP00000354458; ENSG00000157131.
DR   GeneID; 731; -.
DR   KEGG; hsa:731; -.
DR   UCSC; uc001cyo.3; human.
DR   CTD; 731; -.
DR   DisGeNET; 731; -.
DR   EuPathDB; HostDB:ENSG00000157131.10; -.
DR   GeneCards; C8A; -.
DR   HGNC; HGNC:1352; C8A.
DR   MalaCards; C8A; -.
DR   MIM; 120950; gene.
DR   MIM; 613790; phenotype.
DR   neXtProt; NX_P07357; -.
DR   OpenTargets; ENSG00000157131; -.
DR   Orphanet; 169150; Immunodeficiency due to a late component of complements deficiency.
DR   PharmGKB; PA25951; -.
DR   eggNOG; ENOG410IE8U; Eukaryota.
DR   eggNOG; ENOG410Y5MF; LUCA.
DR   GeneTree; ENSGT00550000074478; -.
DR   HOGENOM; HOG000231146; -.
DR   HOVERGEN; HBG005368; -.
DR   InParanoid; P07357; -.
DR   KO; K03997; -.
DR   OMA; ACRCGPC; -.
DR   OrthoDB; EOG091G07LK; -.
DR   PhylomeDB; P07357; -.
DR   TreeFam; TF330498; -.
DR   Reactome; R-HSA-166665; Terminal pathway of complement.
DR   Reactome; R-HSA-977606; Regulation of Complement cascade.
DR   ChiTaRS; C8A; human.
DR   EvolutionaryTrace; P07357; -.
DR   GenomeRNAi; 731; -.
DR   PRO; PR:P07357; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000157131; -.
DR   CleanEx; HS_C8A; -.
DR   Genevisible; P07357; HS.
DR   GO; GO:0072562; C:blood microparticle; HDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; TAS:ProtInc.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0005579; C:membrane attack complex; IDA:UniProtKB.
DR   GO; GO:0001848; F:complement binding; IEA:Ensembl.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0006956; P:complement activation; IDA:MGI.
DR   GO; GO:0006957; P:complement activation, alternative pathway; IEA:UniProtKB-KW.
DR   GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW.
DR   GO; GO:0019835; P:cytolysis; IEA:UniProtKB-KW.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0030449; P:regulation of complement activation; TAS:Reactome.
DR   CDD; cd00112; LDLa; 1.
DR   Gene3D; 2.20.100.10; -; 2.
DR   InterPro; IPR037565; Complement_C8_alpha.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR023415; LDLR_class-A_CS.
DR   InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR   InterPro; IPR001862; MAC_perforin.
DR   InterPro; IPR020864; MACPF.
DR   InterPro; IPR020863; MACPF_CS.
DR   InterPro; IPR000884; TSP1_rpt.
DR   InterPro; IPR036383; TSP1_rpt_sf.
DR   PANTHER; PTHR19325:SF385; PTHR19325:SF385; 1.
DR   Pfam; PF00057; Ldl_recept_a; 1.
DR   Pfam; PF01823; MACPF; 1.
DR   Pfam; PF00090; TSP_1; 1.
DR   PRINTS; PR00764; COMPLEMENTC9.
DR   SMART; SM00192; LDLa; 1.
DR   SMART; SM00457; MACPF; 1.
DR   SMART; SM00209; TSP1; 2.
DR   SUPFAM; SSF57184; SSF57184; 3.
DR   SUPFAM; SSF82895; SSF82895; 2.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01209; LDLRA_1; 1.
DR   PROSITE; PS50068; LDLRA_2; 1.
DR   PROSITE; PS00279; MACPF_1; 1.
DR   PROSITE; PS51412; MACPF_2; 1.
DR   PROSITE; PS50092; TSP1; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Cleavage on pair of basic residues;
KW   Complement alternate pathway; Complement pathway; Complete proteome;
KW   Cytolysis; Direct protein sequencing; Disulfide bond; EGF-like domain;
KW   Glycoprotein; Immunity; Innate immunity; Membrane;
KW   Membrane attack complex; Polymorphism; Reference proteome; Repeat;
KW   Secreted; Signal; Transmembrane; Transmembrane beta strand.
FT   SIGNAL        1     20       {ECO:0000255}.
FT   PROPEP       21     30       {ECO:0000255}.
FT                                /FTId=PRO_0000023585.
FT   CHAIN        31    584       Complement component C8 alpha chain.
FT                                /FTId=PRO_0000023586.
FT   DOMAIN       38     91       TSP type-1 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN       94    132       LDL-receptor class A.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      135    498       MACPF. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00745}.
FT   DOMAIN      499    529       EGF-like.
FT   DOMAIN      539    583       TSP type-1 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   SITE         43     43       Not glycosylated.
FT   CARBOHYD     44     44       C-linked (Man) tryptophan.
FT                                {ECO:0000269|PubMed:10551839}.
FT   CARBOHYD    437    437       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    542    542       C-linked (Man) tryptophan.
FT                                {ECO:0000269|PubMed:10551839}.
FT   CARBOHYD    545    545       C-linked (Man) tryptophan.
FT                                {ECO:0000269|PubMed:10551839}.
FT   CARBOHYD    548    548       C-linked (Man) tryptophan.
FT                                {ECO:0000269|PubMed:10551839}.
FT   DISULFID     39     74       {ECO:0000250}.
FT   DISULFID     50     53       {ECO:0000250}.
FT   DISULFID     84     90       {ECO:0000250}.
FT   DISULFID     96    108       {ECO:0000250}.
FT   DISULFID    102    121       {ECO:0000250}.
FT   DISULFID    115    130       {ECO:0000250}.
FT   DISULFID    140    177
FT   DISULFID    194    194       Interchain (with C-60 in C8-gamma chain).
FT   DISULFID    375    399
FT   VARIANT      93     93       Q -> K (in allele C8A*B; dbSNP:rs652785).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:7649542}.
FT                                /FTId=VAR_011889.
FT   VARIANT     407    407       T -> I (in dbSNP:rs706479).
FT                                /FTId=VAR_011890.
FT   VARIANT     458    458       D -> N (in dbSNP:rs17114555).
FT                                /FTId=VAR_033800.
FT   VARIANT     485    485       R -> L (in dbSNP:rs1620075).
FT                                /FTId=VAR_011891.
FT   VARIANT     561    561       E -> Q (in dbSNP:rs1342440).
FT                                /FTId=VAR_011892.
FT   VARIANT     575    575       P -> L (in dbSNP:rs17300936).
FT                                /FTId=VAR_033801.
FT   CONFLICT    575    575       P -> S (in Ref. 3; AAA82124).
FT                                {ECO:0000305}.
FT   TURN         52     54       {ECO:0000244|PDB:3OJY}.
FT   STRAND       56     60       {ECO:0000244|PDB:3OJY}.
FT   STRAND       63     65       {ECO:0000244|PDB:3OJY}.
FT   STRAND       78     83       {ECO:0000244|PDB:3OJY}.
FT   STRAND       97    101       {ECO:0000244|PDB:3OJY}.
FT   STRAND      103    105       {ECO:0000244|PDB:3OJY}.
FT   HELIX       111    113       {ECO:0000244|PDB:3OJY}.
FT   STRAND      116    118       {ECO:0000244|PDB:3OJY}.
FT   STRAND      121    123       {ECO:0000244|PDB:3OJY}.
FT   STRAND      127    129       {ECO:0000244|PDB:3OJY}.
FT   STRAND      140    143       {ECO:0000244|PDB:2QQH}.
FT   HELIX       149    152       {ECO:0000244|PDB:2RD7}.
FT   STRAND      154    157       {ECO:0000244|PDB:2RD7}.
FT   TURN        158    161       {ECO:0000244|PDB:2RD7}.
FT   STRAND      162    168       {ECO:0000244|PDB:2RD7}.
FT   STRAND      179    182       {ECO:0000244|PDB:2RD7}.
FT   TURN        183    186       {ECO:0000244|PDB:2QQH}.
FT   STRAND      189    191       {ECO:0000244|PDB:2QOS}.
FT   TURN        192    195       {ECO:0000244|PDB:2QOS}.
FT   STRAND      196    198       {ECO:0000244|PDB:2QOS}.
FT   HELIX       201    203       {ECO:0000244|PDB:3OJY}.
FT   STRAND      204    207       {ECO:0000244|PDB:2RD7}.
FT   STRAND      212    217       {ECO:0000244|PDB:2RD7}.
FT   STRAND      226    232       {ECO:0000244|PDB:2RD7}.
FT   HELIX       233    243       {ECO:0000244|PDB:2RD7}.
FT   STRAND      246    252       {ECO:0000244|PDB:2RD7}.
FT   STRAND      260    266       {ECO:0000244|PDB:2RD7}.
FT   HELIX       273    280       {ECO:0000244|PDB:2RD7}.
FT   STRAND      287    303       {ECO:0000244|PDB:2RD7}.
FT   STRAND      305    308       {ECO:0000244|PDB:2RD7}.
FT   HELIX       312    319       {ECO:0000244|PDB:2RD7}.
FT   HELIX       327    337       {ECO:0000244|PDB:2RD7}.
FT   STRAND      339    358       {ECO:0000244|PDB:2RD7}.
FT   HELIX       359    365       {ECO:0000244|PDB:2RD7}.
FT   HELIX       369    379       {ECO:0000244|PDB:2RD7}.
FT   HELIX       398    402       {ECO:0000244|PDB:2RD7}.
FT   HELIX       408    413       {ECO:0000244|PDB:2RD7}.
FT   STRAND      416    421       {ECO:0000244|PDB:2RD7}.
FT   HELIX       443    449       {ECO:0000244|PDB:2RD7}.
FT   TURN        450    452       {ECO:0000244|PDB:2RD7}.
FT   STRAND      455    463       {ECO:0000244|PDB:2RD7}.
FT   HELIX       464    470       {ECO:0000244|PDB:2RD7}.
FT   HELIX       477    491       {ECO:0000244|PDB:2RD7}.
FT   HELIX       496    498       {ECO:0000244|PDB:3OJY}.
FT   TURN        503    505       {ECO:0000244|PDB:3OJY}.
FT   STRAND      508    511       {ECO:0000244|PDB:3OJY}.
FT   STRAND      514    517       {ECO:0000244|PDB:3OJY}.
FT   STRAND      525    527       {ECO:0000244|PDB:3OJY}.
FT   STRAND      552    554       {ECO:0000244|PDB:3OJY}.
FT   STRAND      556    559       {ECO:0000244|PDB:3OJY}.
FT   STRAND      578    582       {ECO:0000244|PDB:3OJY}.
SQ   SEQUENCE   584 AA;  65163 MW;  9F61DDA51D2F3BBA CRC64;
     MFAVVFFILS LMTCQPGVTA QEKVNQRVRR AATPAAVTCQ LSNWSEWTDC FPCQDKKYRH
     RSLLQPNKFG GTICSGDIWD QASCSSSTTC VRQAQCGQDF QCKETGRCLK RHLVCNGDQD
     CLDGSDEDDC EDVRAIDEDC SQYEPIPGSQ KAALGYNILT QEDAQSVYDA SYYGGQCETV
     YNGEWRELRY DSTCERLYYG DDEKYFRKPY NFLKYHFEAL ADTGISSEFY DNANDLLSKV
     KKDKSDSFGV TIGIGPAGSP LLVGVGVSHS QDTSFLNELN KYNEKKFIFT RIFTKVQTAH
     FKMRKDDIML DEGMLQSLME LPDQYNYGMY AKFINDYGTH YITSGSMGGI YEYILVIDKA
     KMESLGITSR DITTCFGGSL GIQYEDKINV GGGLSGDHCK KFGGGKTERA RKAMAVEDII
     SRVRGGSSGW SGGLAQNRST ITYRSWGRSL KYNPVVIDFE MQPIHEVLRH TSLGPLEAKR
     QNLRRALDQY LMEFNACRCG PCFNNGVPIL EGTSCRCQCR LGSLGAACEQ TQTEGAKADG
     SWSCWSSWSV CRAGIQERRR ECDNPAPQNG GASCPGRKVQ TQAC
//
ID   CO8B_HUMAN              Reviewed;         591 AA.
AC   P07358; A1L4K7;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2002, sequence version 3.
DT   20-JUN-2018, entry version 182.
DE   RecName: Full=Complement component C8 beta chain;
DE   AltName: Full=Complement component 8 subunit beta;
DE   Flags: Precursor;
GN   Name=C8B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND
RP   GLYCOSYLATION.
RC   TISSUE=Liver;
RX   PubMed=2820472; DOI=10.1021/bi00386a047;
RA   Howard O.M.Z., Rao A.G., Sodetz J.M.;
RT   "Complementary DNA and derived amino acid sequence of the beta subunit
RT   of human complement protein C8: identification of a close structural
RT   and ancestral relationship to the alpha subunit and C9.";
RL   Biochemistry 26:3565-3570(1987).
RN   [2]
RP   SEQUENCE REVISION.
RA   Sodetz J.M.;
RL   Submitted (JUN-1988) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLY-117.
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 47-591, AND PROTEIN SEQUENCE OF 55-68.
RC   TISSUE=Liver;
RX   PubMed=3651397; DOI=10.1021/bi00386a045;
RA   Haefliger J.-A., Tschopp J., Nardelli D., Wahli W., Kocher H.-P.,
RA   Tosi M., Stanley K.K.;
RT   "Complementary DNA cloning of complement C8 beta and its sequence
RT   homology to C9.";
RL   Biochemistry 26:3551-3556(1987).
RN   [8]
RP   PARTIAL PROTEIN SEQUENCE, CHARACTERIZATION, AND SUBUNIT.
RX   PubMed=7440581;
RA   Steckel E.W., York R.G., Monahan J.B., Sodetz J.M.;
RT   "The eighth component of human complement. Purification and
RT   physicochemical characterization of its unusual subunit structure.";
RL   J. Biol. Chem. 255:11997-12005(1980).
RN   [9]
RP   GLYCOSYLATION AT TRP-70; TRP-73; TRP-551 AND TRP-554.
RX   PubMed=10551839; DOI=10.1074/jbc.274.46.32786;
RA   Hofsteenge J., Blommers M., Hess D., Furmanek A., Miroshnichenko O.;
RT   "The four terminal components of the complement system are C-
RT   mannosylated on multiple tryptophan residues.";
RL   J. Biol. Chem. 274:32786-32794(1999).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-243.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [11]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-243.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.51 ANGSTROMS) OF 55-591, PHOSPHORYLATION AT
RP   THR-418, SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=21454577; DOI=10.1074/jbc.M111.219766;
RA   Lovelace L.L., Cooper C.L., Sodetz J.M., Lebioda L.;
RT   "Structure of human C8 protein provides mechanistic insight into
RT   membrane pore formation by complement.";
RL   J. Biol. Chem. 286:17585-17592(2011).
RN   [14]
RP   VARIANT GLY-117, AND DEFINITION OF ALLOTYPES C8B A AND C8B B.
RX   PubMed=8131848; DOI=10.1016/0014-5793(94)80140-1;
RA   Dewald G., Hemmer S., Noethen M.M.;
RT   "Human complement component C8. Molecular basis of the beta-chain
RT   polymorphism.";
RL   FEBS Lett. 340:211-215(1994).
CC   -!- FUNCTION: Constituent of the membrane attack complex (MAC) that
CC       plays a key role in the innate and adaptive immune response by
CC       forming pores in the plasma membrane of target cells.
CC   -!- SUBUNIT: Heterotrimer of 3 chains: alpha, beta and gamma. The
CC       alpha and gamma chains are disulfide bonded. Component of the
CC       membrane attack complex (MAC). MAC assembly is initiated by
CC       proteolytic cleavage of C5 into C5a and C5b. C5b binds
CC       sequentially C6, C7, C8 and multiple copies of the pore-forming
CC       subunit C9. {ECO:0000269|PubMed:21454577,
CC       ECO:0000269|PubMed:7440581}.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- PTM: N-glycosylated; contains one or two bound glycans. Not O-
CC       glycosylated. {ECO:0000269|PubMed:10551839,
CC       ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:2820472}.
CC   -!- POLYMORPHISM: The sequence shown is that of allotype C8B B.
CC   -!- DISEASE: Complement component 8 deficiency, 2 (C8D2) [MIM:613789]:
CC       A rare defect of the complement classical pathway associated with
CC       susceptibility to severe recurrent infections, predominantly by
CC       Neisseria gonorrhoeae or Neisseria meningitidis. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the complement C6/C7/C8/C9 family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=C8Bbase; Note=C8B mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/C8Bbase/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; M16973; AAA51862.1; -; mRNA.
DR   EMBL; AK313382; BAG36180.1; -; mRNA.
DR   EMBL; AL121998; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471059; EAX06641.1; -; Genomic_DNA.
DR   EMBL; BC130575; AAI30576.1; -; mRNA.
DR   EMBL; X04393; CAA27981.1; -; mRNA.
DR   CCDS; CCDS30730.1; -.
DR   PIR; A43071; C8HUB.
DR   RefSeq; NP_000057.2; NM_000066.3.
DR   RefSeq; XP_016857724.1; XM_017002235.1.
DR   UniGene; Hs.391835; -.
DR   PDB; 3OJY; X-ray; 2.51 A; B=55-591.
DR   PDBsum; 3OJY; -.
DR   ProteinModelPortal; P07358; -.
DR   SMR; P07358; -.
DR   BioGrid; 107193; 6.
DR   STRING; 9606.ENSP00000360281; -.
DR   iPTMnet; P07358; -.
DR   PhosphoSitePlus; P07358; -.
DR   DMDM; 20141201; -.
DR   PaxDb; P07358; -.
DR   PeptideAtlas; P07358; -.
DR   PRIDE; P07358; -.
DR   ProteomicsDB; 51998; -.
DR   DNASU; 732; -.
DR   Ensembl; ENST00000371237; ENSP00000360281; ENSG00000021852.
DR   GeneID; 732; -.
DR   KEGG; hsa:732; -.
DR   UCSC; uc001cyp.5; human.
DR   CTD; 732; -.
DR   DisGeNET; 732; -.
DR   EuPathDB; HostDB:ENSG00000021852.12; -.
DR   GeneCards; C8B; -.
DR   HGNC; HGNC:1353; C8B.
DR   HPA; HPA023694; -.
DR   MalaCards; C8B; -.
DR   MIM; 120960; gene.
DR   MIM; 613789; phenotype.
DR   neXtProt; NX_P07358; -.
DR   Orphanet; 169150; Immunodeficiency due to a late component of complements deficiency.
DR   PharmGKB; PA25952; -.
DR   eggNOG; ENOG410IE7H; Eukaryota.
DR   eggNOG; ENOG410Y2J1; LUCA.
DR   HOGENOM; HOG000231146; -.
DR   HOVERGEN; HBG106489; -.
DR   InParanoid; P07358; -.
DR   KO; K03998; -.
DR   OrthoDB; EOG091G07LK; -.
DR   PhylomeDB; P07358; -.
DR   TreeFam; TF330498; -.
DR   Reactome; R-HSA-166665; Terminal pathway of complement.
DR   Reactome; R-HSA-977606; Regulation of Complement cascade.
DR   ChiTaRS; C8B; human.
DR   EvolutionaryTrace; P07358; -.
DR   GenomeRNAi; 732; -.
DR   PRO; PR:P07358; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000021852; -.
DR   CleanEx; HS_C8B; -.
DR   ExpressionAtlas; P07358; baseline and differential.
DR   Genevisible; P07358; HS.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1903561; C:extracellular vesicle; HDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0005579; C:membrane attack complex; IDA:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0006956; P:complement activation; TAS:ProtInc.
DR   GO; GO:0006957; P:complement activation, alternative pathway; IEA:UniProtKB-KW.
DR   GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW.
DR   GO; GO:0019835; P:cytolysis; IEA:UniProtKB-KW.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0030449; P:regulation of complement activation; TAS:Reactome.
DR   CDD; cd00112; LDLa; 1.
DR   Gene3D; 2.20.100.10; -; 2.
DR   InterPro; IPR037566; Complement_C8_beta.
DR   InterPro; IPR036055; LDL_receptor-like_sf.
DR   InterPro; IPR023415; LDLR_class-A_CS.
DR   InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR   InterPro; IPR001862; MAC_perforin.
DR   InterPro; IPR020864; MACPF.
DR   InterPro; IPR020863; MACPF_CS.
DR   InterPro; IPR000884; TSP1_rpt.
DR   InterPro; IPR036383; TSP1_rpt_sf.
DR   PANTHER; PTHR19325:SF401; PTHR19325:SF401; 1.
DR   Pfam; PF00057; Ldl_recept_a; 1.
DR   Pfam; PF01823; MACPF; 1.
DR   Pfam; PF00090; TSP_1; 2.
DR   PRINTS; PR00764; COMPLEMENTC9.
DR   SMART; SM00192; LDLa; 1.
DR   SMART; SM00457; MACPF; 1.
DR   SMART; SM00209; TSP1; 2.
DR   SUPFAM; SSF57424; SSF57424; 1.
DR   SUPFAM; SSF82895; SSF82895; 2.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01209; LDLRA_1; 1.
DR   PROSITE; PS50068; LDLRA_2; 1.
DR   PROSITE; PS00279; MACPF_1; 1.
DR   PROSITE; PS51412; MACPF_2; 1.
DR   PROSITE; PS50092; TSP1; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Complement alternate pathway; Complement pathway;
KW   Complete proteome; Cytolysis; Direct protein sequencing;
KW   Disulfide bond; EGF-like domain; Glycoprotein; Immunity;
KW   Innate immunity; Membrane attack complex; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Secreted; Signal.
FT   SIGNAL        1     32       {ECO:0000255}.
FT   PROPEP       33     54       {ECO:0000269|PubMed:3651397}.
FT                                /FTId=PRO_0000023591.
FT   CHAIN        55    591       Complement component C8 beta chain.
FT                                /FTId=PRO_0000023592.
FT   DOMAIN       64    117       TSP type-1 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN      120    157       LDL-receptor class A.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      158    504       MACPF. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00745}.
FT   DOMAIN      505    535       EGF-like.
FT   DOMAIN      545    591       TSP type-1 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   MOD_RES     418    418       Phosphothreonine.
FT                                {ECO:0000269|PubMed:21454577}.
FT   CARBOHYD     70     70       C-linked (Man) tryptophan.
FT                                {ECO:0000269|PubMed:10551839}.
FT   CARBOHYD     73     73       C-linked (Man) tryptophan.
FT                                {ECO:0000269|PubMed:10551839}.
FT   CARBOHYD    101    101       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    243    243       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    551    551       C-linked (Man) tryptophan.
FT                                {ECO:0000269|PubMed:10551839}.
FT   CARBOHYD    554    554       C-linked (Man) tryptophan.
FT                                {ECO:0000269|PubMed:10551839}.
FT   DISULFID     65    100       {ECO:0000269|PubMed:21454577}.
FT   DISULFID     76    110       {ECO:0000269|PubMed:21454577}.
FT   DISULFID     79    116       {ECO:0000269|PubMed:21454577}.
FT   DISULFID    122    133       {ECO:0000269|PubMed:21454577}.
FT   DISULFID    127    146       {ECO:0000269|PubMed:21454577}.
FT   DISULFID    140    155       {ECO:0000269|PubMed:21454577}.
FT   DISULFID    378    403       {ECO:0000269|PubMed:21454577}.
FT   DISULFID    503    550       {ECO:0000269|PubMed:21454577}.
FT   DISULFID    505    521       {ECO:0000269|PubMed:21454577}.
FT   DISULFID    508    523       {ECO:0000269|PubMed:21454577}.
FT   DISULFID    525    534       {ECO:0000269|PubMed:21454577}.
FT   DISULFID    557    590       {ECO:0000269|PubMed:21454577}.
FT   VARIANT     108    108       E -> K (in dbSNP:rs12067507).
FT                                /FTId=VAR_027649.
FT   VARIANT     117    117       R -> G (in allotype C8B A;
FT                                dbSNP:rs1013579).
FT                                {ECO:0000269|PubMed:16710414,
FT                                ECO:0000269|PubMed:8131848}.
FT                                /FTId=VAR_012642.
FT   VARIANT     261    261       P -> L (in dbSNP:rs12085435).
FT                                /FTId=VAR_027650.
FT   TURN         78     81       {ECO:0000244|PDB:3OJY}.
FT   STRAND       82     86       {ECO:0000244|PDB:3OJY}.
FT   STRAND       89     91       {ECO:0000244|PDB:3OJY}.
FT   STRAND      104    109       {ECO:0000244|PDB:3OJY}.
FT   STRAND      123    126       {ECO:0000244|PDB:3OJY}.
FT   TURN        128    130       {ECO:0000244|PDB:3OJY}.
FT   HELIX       136    138       {ECO:0000244|PDB:3OJY}.
FT   STRAND      141    143       {ECO:0000244|PDB:3OJY}.
FT   STRAND      146    149       {ECO:0000244|PDB:3OJY}.
FT   HELIX       172    176       {ECO:0000244|PDB:3OJY}.
FT   STRAND      177    179       {ECO:0000244|PDB:3OJY}.
FT   TURN        181    183       {ECO:0000244|PDB:3OJY}.
FT   STRAND      186    189       {ECO:0000244|PDB:3OJY}.
FT   STRAND      201    205       {ECO:0000244|PDB:3OJY}.
FT   STRAND      208    212       {ECO:0000244|PDB:3OJY}.
FT   STRAND      216    221       {ECO:0000244|PDB:3OJY}.
FT   STRAND      229    236       {ECO:0000244|PDB:3OJY}.
FT   HELIX       237    240       {ECO:0000244|PDB:3OJY}.
FT   TURN        256    258       {ECO:0000244|PDB:3OJY}.
FT   TURN        269    271       {ECO:0000244|PDB:3OJY}.
FT   STRAND      272    275       {ECO:0000244|PDB:3OJY}.
FT   HELIX       276    283       {ECO:0000244|PDB:3OJY}.
FT   STRAND      290    297       {ECO:0000244|PDB:3OJY}.
FT   STRAND      299    306       {ECO:0000244|PDB:3OJY}.
FT   STRAND      308    310       {ECO:0000244|PDB:3OJY}.
FT   HELIX       315    321       {ECO:0000244|PDB:3OJY}.
FT   HELIX       330    340       {ECO:0000244|PDB:3OJY}.
FT   STRAND      342    352       {ECO:0000244|PDB:3OJY}.
FT   STRAND      355    361       {ECO:0000244|PDB:3OJY}.
FT   HELIX       362    365       {ECO:0000244|PDB:3OJY}.
FT   TURN        366    369       {ECO:0000244|PDB:3OJY}.
FT   HELIX       372    378       {ECO:0000244|PDB:3OJY}.
FT   TURN        379    381       {ECO:0000244|PDB:3OJY}.
FT   TURN        404    408       {ECO:0000244|PDB:3OJY}.
FT   HELIX       409    412       {ECO:0000244|PDB:3OJY}.
FT   TURN        413    415       {ECO:0000244|PDB:3OJY}.
FT   STRAND      419    426       {ECO:0000244|PDB:3OJY}.
FT   HELIX       435    439       {ECO:0000244|PDB:3OJY}.
FT   STRAND      441    443       {ECO:0000244|PDB:3OJY}.
FT   HELIX       449    457       {ECO:0000244|PDB:3OJY}.
FT   STRAND      461    469       {ECO:0000244|PDB:3OJY}.
FT   HELIX       470    473       {ECO:0000244|PDB:3OJY}.
FT   TURN        476    478       {ECO:0000244|PDB:3OJY}.
FT   HELIX       482    499       {ECO:0000244|PDB:3OJY}.
FT   HELIX       502    504       {ECO:0000244|PDB:3OJY}.
FT   STRAND      513    517       {ECO:0000244|PDB:3OJY}.
FT   STRAND      520    524       {ECO:0000244|PDB:3OJY}.
FT   HELIX       532    534       {ECO:0000244|PDB:3OJY}.
FT   STRAND      536    541       {ECO:0000244|PDB:3OJY}.
FT   STRAND      557    563       {ECO:0000244|PDB:3OJY}.
FT   STRAND      584    588       {ECO:0000244|PDB:3OJY}.
SQ   SEQUENCE   591 AA;  67047 MW;  B01722A6F2E9AFCE CRC64;
     MKNSRTWAWR APVELFLLCA ALGCLSLPGS RGERPHSFGS NAVNKSFAKS RQMRSVDVTL
     MPIDCELSSW SSWTTCDPCQ KKRYRYAYLL QPSQFHGEPC NFSDKEVEDC VTNRPCRSQV
     RCEGFVCAQT GRCVNRRLLC NGDNDCGDQS DEANCRRIYK KCQHEMDQYW GIGSLASGIN
     LFTNSFEGPV LDHRYYAGGC SPHYILNTRF RKPYNVESYT PQTQGKYEFI LKEYESYSDF
     ERNVTEKMAS KSGFSFGFKI PGIFELGISS QSDRGKHYIR RTKRFSHTKS VFLHARSDLE
     VAHYKLKPRS LMLHYEFLQR VKRLPLEYSY GEYRDLFRDF GTHYITEAVL GGIYEYTLVM
     NKEAMERGDY TLNNVHACAK NDFKIGGAIE EVYVSLGVSV GKCRGILNEI KDRNKRDTMV
     EDLVVLVRGG ASEHITTLAY QELPTADLMQ EWGDAVQYNP AIIKVKVEPL YELVTATDFA
     YSSTVRQNMK QALEEFQKEV SSCHCAPCQG NGVPVLKGSR CDCICPVGSQ GLACEVSYRK
     NTPIDGKWNC WSNWSSCSGR RKTRQRQCNN PPPQNGGSPC SGPASETLDC S
//
ID   CO8G_HUMAN              Reviewed;         202 AA.
AC   P07360; Q14CT8; Q14CU0; Q5SQ07;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2006, sequence version 3.
DT   20-JUN-2018, entry version 187.
DE   RecName: Full=Complement component C8 gamma chain;
DE   Flags: Precursor;
GN   Name=C8G;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, PYROGLUTAMATE
RP   FORMATION AT GLN-21, AND VARIANT GLY-118.
RX   PubMed=3676249; DOI=10.1021/bi00391a003;
RA   Ng S.C., Rao A.G., Howard O.M.Z., Sodetz J.M.;
RT   "The eighth component of human complement: evidence that it is an
RT   oligomeric serum protein assembled from products of three different
RT   genes.";
RL   Biochemistry 26:5229-5233(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT GLY-118.
RC   TISSUE=Liver;
RX   PubMed=2447883; DOI=10.1016/0006-291X(87)90431-1;
RA   Haefliger J.-A., Jenne D.E., Stanley K.K., Tschopp J.;
RT   "Structural homology of human complement component C8 gamma and plasma
RT   protein HC: identity of the cysteine bond pattern.";
RL   Biochem. Biophys. Res. Commun. 149:750-754(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLY-118.
RC   TISSUE=Blood;
RX   PubMed=8172891; DOI=10.1021/bi00183a020;
RA   Kaufman K.M., Sodetz J.M.;
RT   "Genomic structure of the human complement protein C8 gamma: homology
RT   to the lipocalin gene family.";
RL   Biochemistry 33:5162-5166(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLY-118.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS GLY-118 AND
RP   ASN-124.
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   SIMILARITY TO LIPOCALINS.
RX   PubMed=2446620; DOI=10.1016/0006-291X(87)91636-6;
RA   Hunt L.T., Elzanowski A., Barker W.C.;
RT   "The homology of complement factor C8 gamma chain and alpha-1-
RT   microglobulin.";
RL   Biochem. Biophys. Res. Commun. 149:282-288(1987).
RN   [8]
RP   DISULFIDE BONDS, RETINOL-BINDING, AND 3D-STRUCTURE MODELING.
RX   PubMed=1707134; DOI=10.1016/0161-5890(91)90095-2;
RA   Haefliger J.-A., Peitsch M.C., Jenne D.E., Tschopp J.;
RT   "Structural and functional characterization of complement C8 gamma, a
RT   member of the lipocalin protein family.";
RL   Mol. Immunol. 28:123-131(1991).
RN   [9]
RP   REVIEW.
RX   PubMed=11058761; DOI=10.1016/S0167-4838(00)00155-2;
RA   Schreck S.F., Parker C., Plumb M.E., Sodetz J.M.;
RT   "Human complement protein C8 gamma.";
RL   Biochim. Biophys. Acta 1482:199-208(2000).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.2 ANGSTROMS) OF 21-202, AND DISULFIDE BOND.
RX   PubMed=12033936; DOI=10.1021/bi025696i;
RA   Ortlund E., Parker C.L., Schreck S.F., Ginell S., Minor W.,
RA   Sodetz J.M., Lebioda L.;
RT   "Crystal structure of human complement protein C8gamma at 1.2 A
RT   resolution reveals a lipocalin fold and a distinct ligand binding
RT   site.";
RL   Biochemistry 41:7030-7037(2002).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 21-202, AND DISULFIDE BOND.
RX   PubMed=17452033; DOI=10.1016/j.bbapap.2007.03.004;
RA   Chiswell B., Lovelace L.L., Brannen C., Ortlund E.A., Lebioda L.,
RA   Sodetz J.M.;
RT   "Structural features of the ligand binding site on human complement
RT   protein C8gamma: a member of the lipocalin family.";
RL   Biochim. Biophys. Acta 1774:637-644(2007).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.81 ANGSTROMS) OF 30-202, AND DISULFIDE BOND.
RX   PubMed=17692377; DOI=10.1016/j.molimm.2007.06.359;
RA   Lovelace L.L., Chiswell B., Slade D.J., Sodetz J.M., Lebioda L.;
RT   "Crystal structure of complement protein C8gamma in complex with a
RT   peptide containing the C8gamma binding site on C8alpha: implications
RT   for C8gamma ligand binding.";
RL   Mol. Immunol. 45:750-756(2008).
CC   -!- FUNCTION: C8 is a constituent of the membrane attack complex. C8
CC       binds to the C5B-7 complex, forming the C5B-8 complex. C5-B8 binds
CC       C9 and acts as a catalyst in the polymerization of C9. The gamma
CC       subunit seems to be able to bind retinol.
CC   -!- SUBUNIT: C8 is composed of three chains: alpha, beta and gamma.
CC       The alpha and gamma chains are disulfide bonded.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- SIMILARITY: Belongs to the calycin superfamily. Lipocalin family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; M17263; AAA51888.1; -; mRNA.
DR   EMBL; M17999; AAA51863.1; -; mRNA.
DR   EMBL; X06465; CAA29773.1; -; mRNA.
DR   EMBL; U08198; AAA18482.1; -; Genomic_DNA.
DR   EMBL; AL807752; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471090; EAW88316.1; -; Genomic_DNA.
DR   EMBL; BC113624; AAI13625.1; -; mRNA.
DR   EMBL; BC113626; AAI13627.1; -; mRNA.
DR   CCDS; CCDS7017.1; -.
DR   PIR; A27487; C8HUG.
DR   RefSeq; NP_000597.2; NM_000606.2.
DR   UniGene; Hs.1285; -.
DR   PDB; 1IW2; X-ray; 1.90 A; A=21-202.
DR   PDB; 1LF7; X-ray; 1.20 A; A=21-202.
DR   PDB; 2OVA; X-ray; 1.50 A; A=21-202.
DR   PDB; 2OVD; X-ray; 1.80 A; A=21-202.
DR   PDB; 2OVE; X-ray; 2.00 A; A=21-202.
DR   PDB; 2QOS; X-ray; 1.81 A; C=30-202.
DR   PDB; 2RD7; X-ray; 2.15 A; C=21-202.
DR   PDB; 3OJY; X-ray; 2.51 A; C=21-202.
DR   PDBsum; 1IW2; -.
DR   PDBsum; 1LF7; -.
DR   PDBsum; 2OVA; -.
DR   PDBsum; 2OVD; -.
DR   PDBsum; 2OVE; -.
DR   PDBsum; 2QOS; -.
DR   PDBsum; 2RD7; -.
DR   PDBsum; 3OJY; -.
DR   ProteinModelPortal; P07360; -.
DR   SMR; P07360; -.
DR   BioGrid; 107194; 6.
DR   IntAct; P07360; 1.
DR   STRING; 9606.ENSP00000224181; -.
DR   DrugBank; DB04272; Citric Acid.
DR   DrugBank; DB03017; Lauric Acid.
DR   iPTMnet; P07360; -.
DR   PhosphoSitePlus; P07360; -.
DR   BioMuta; C8G; -.
DR   PaxDb; P07360; -.
DR   PeptideAtlas; P07360; -.
DR   PRIDE; P07360; -.
DR   ProteomicsDB; 52000; -.
DR   DNASU; 733; -.
DR   Ensembl; ENST00000224181; ENSP00000224181; ENSG00000176919.
DR   GeneID; 733; -.
DR   KEGG; hsa:733; -.
DR   UCSC; uc004cka.3; human.
DR   CTD; 733; -.
DR   DisGeNET; 733; -.
DR   EuPathDB; HostDB:ENSG00000176919.11; -.
DR   GeneCards; C8G; -.
DR   H-InvDB; HIX0201411; -.
DR   HGNC; HGNC:1354; C8G.
DR   HPA; HPA046269; -.
DR   MalaCards; C8G; -.
DR   MIM; 120930; gene.
DR   neXtProt; NX_P07360; -.
DR   OpenTargets; ENSG00000176919; -.
DR   Orphanet; 169150; Immunodeficiency due to a late component of complements deficiency.
DR   PharmGKB; PA25953; -.
DR   eggNOG; ENOG410IX6K; Eukaryota.
DR   eggNOG; ENOG4111Y9C; LUCA.
DR   GeneTree; ENSGT00440000034309; -.
DR   HOGENOM; HOG000111143; -.
DR   HOVERGEN; HBG005369; -.
DR   InParanoid; P07360; -.
DR   KO; K03999; -.
DR   OMA; GSACRFL; -.
DR   OrthoDB; EOG091G0QPN; -.
DR   PhylomeDB; P07360; -.
DR   TreeFam; TF336103; -.
DR   Reactome; R-HSA-166665; Terminal pathway of complement.
DR   Reactome; R-HSA-977606; Regulation of Complement cascade.
DR   EvolutionaryTrace; P07360; -.
DR   GenomeRNAi; 733; -.
DR   PRO; PR:P07360; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000176919; -.
DR   CleanEx; HS_C8G; -.
DR   ExpressionAtlas; P07360; baseline and differential.
DR   Genevisible; P07360; HS.
DR   GO; GO:0072562; C:blood microparticle; HDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005579; C:membrane attack complex; IEA:UniProtKB-KW.
DR   GO; GO:0001848; F:complement binding; IEA:Ensembl.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0019841; F:retinol binding; IEA:UniProtKB-KW.
DR   GO; GO:0006957; P:complement activation, alternative pathway; IEA:UniProtKB-KW.
DR   GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW.
DR   GO; GO:0019835; P:cytolysis; IEA:UniProtKB-KW.
DR   GO; GO:0030449; P:regulation of complement activation; TAS:Reactome.
DR   Gene3D; 2.40.128.20; -; 1.
DR   InterPro; IPR002968; A1-microglobln.
DR   InterPro; IPR012674; Calycin.
DR   InterPro; IPR002345; Lipocalin.
DR   InterPro; IPR022272; Lipocalin_CS.
DR   InterPro; IPR000566; Lipocln_cytosolic_FA-bd_dom.
DR   PANTHER; PTHR11430; PTHR11430; 1.
DR   Pfam; PF00061; Lipocalin; 1.
DR   PRINTS; PR01215; A1MCGLOBULIN.
DR   SUPFAM; SSF50814; SSF50814; 1.
DR   PROSITE; PS00213; LIPOCALIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complement alternate pathway; Complement pathway;
KW   Complete proteome; Cytolysis; Direct protein sequencing;
KW   Disulfide bond; Immunity; Innate immunity; Membrane attack complex;
KW   Polymorphism; Pyrrolidone carboxylic acid; Reference proteome;
KW   Retinol-binding; Secreted; Signal.
FT   SIGNAL        1     20
FT   CHAIN        21    202       Complement component C8 gamma chain.
FT                                /FTId=PRO_0000017881.
FT   MOD_RES      21     21       Pyrrolidone carboxylic acid.
FT                                {ECO:0000269|PubMed:3676249}.
FT   DISULFID     60     60       Interchain (with C-194 in C8-alpha
FT                                chain).
FT   DISULFID     96    188
FT   VARIANT      69     69       R -> Q (in dbSNP:rs17614).
FT                                /FTId=VAR_014668.
FT   VARIANT     118    118       D -> G (in dbSNP:rs7850844).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:2447883,
FT                                ECO:0000269|PubMed:3676249,
FT                                ECO:0000269|PubMed:8172891,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_044319.
FT   VARIANT     124    124       H -> N (in dbSNP:rs17613).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_014669.
FT   HELIX        32     35       {ECO:0000244|PDB:1LF7}.
FT   HELIX        44     47       {ECO:0000244|PDB:1LF7}.
FT   STRAND       49     57       {ECO:0000244|PDB:1LF7}.
FT   HELIX        61     66       {ECO:0000244|PDB:2QOS}.
FT   HELIX        67     69       {ECO:0000244|PDB:2QOS}.
FT   STRAND       73     80       {ECO:0000244|PDB:1LF7}.
FT   STRAND       83     92       {ECO:0000244|PDB:1LF7}.
FT   STRAND       95    105       {ECO:0000244|PDB:1LF7}.
FT   STRAND      111    114       {ECO:0000244|PDB:1LF7}.
FT   STRAND      117    121       {ECO:0000244|PDB:1LF7}.
FT   STRAND      123    130       {ECO:0000244|PDB:1LF7}.
FT   STRAND      132    142       {ECO:0000244|PDB:1LF7}.
FT   STRAND      145    156       {ECO:0000244|PDB:1LF7}.
FT   HELIX       159    171       {ECO:0000244|PDB:1LF7}.
FT   HELIX       176    178       {ECO:0000244|PDB:1LF7}.
FT   STRAND      179    181       {ECO:0000244|PDB:1LF7}.
FT   HELIX       193    195       {ECO:0000244|PDB:1LF7}.
FT   STRAND      196    198       {ECO:0000244|PDB:1LF7}.
SQ   SEQUENCE   202 AA;  22277 MW;  4E4F73140E607FFE CRC64;
     MLPPGTATLL TLLLAAGSLG QKPQRPRRPA SPISTIQPKA NFDAQQFAGT WLLVAVGSAC
     RFLQEQGHRA EATTLHVAPQ GTAMAVSTFR KLDGICWQVR QLYGDTGVLG RFLLQARDAR
     GAVHVVVAET DYQSFAVLYL ERAGQLSVKL YARSLPVSDS VLSGFEQRVQ EAHLTEDQIF
     YFPKYGFCEA ADQFHVLDEV RR
//
ID   CO7_HUMAN               Reviewed;         843 AA.
AC   P10643; Q6P3T5; Q92489;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   15-MAR-2005, sequence version 2.
DT   20-JUN-2018, entry version 189.
DE   RecName: Full=Complement component C7;
DE   Flags: Precursor;
GN   Name=C7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND VARIANT
RP   PRO-587.
RX   PubMed=3335508;
RA   Discipio R.G., Chakravari D.N., Mueller-Eberhard H.J., Fey G.H.;
RT   "The structure of human complement component C7 and the C5b-7
RT   complex.";
RL   J. Biol. Chem. 263:549-560(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=PNS;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 3-822, AND VARIANT THR-389.
RX   PubMed=7730625;
RA   Hobart M.J., Fernie B.A., DiScipio R.G.;
RT   "Structure of the human C7 gene and comparison with the C6, C8A, C8B
RT   and C9 genes.";
RL   J. Immunol. 154:5188-5194(1995).
RN   [4]
RP   GLYCOSYLATION AT TRP-36; TRP-503; TRP-506 AND TRP-509.
RX   PubMed=10551839; DOI=10.1074/jbc.274.46.32786;
RA   Hofsteenge J., Blommers M., Hess D., Furmanek A., Miroshnichenko O.;
RT   "The four terminal components of the complement system are C-
RT   mannosylated on multiple tryptophan residues.";
RL   J. Biol. Chem. 274:32786-32794(1999).
RN   [5]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-202.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [6]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-202 AND ASN-754.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [7]
RP   GLYCOSYLATION AT ASN-754.
RX   PubMed=19139490; DOI=10.1074/mcp.M800504-MCP200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F.,
RA   Zheng Z.B., Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y.,
RA   Zhang Y.K., Deng Y.L., Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core
RT   fucosylated glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [8]
RP   GLYCOSYLATION AT THR-696, STRUCTURE OF CARBOHYDRATES, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22171320; DOI=10.1074/mcp.M111.013649;
RA   Halim A., Nilsson J., Ruetschi U., Hesse C., Larson G.;
RT   "Human urinary glycoproteomics; attachment site specific analysis of
RT   N-and O-linked glycosylations by CID and ECD.";
RL   Mol. Cell. Proteomics 11:1-17(2012).
RN   [9]
RP   STRUCTURE BY NMR OF 693-843, AND DISULFIDE BONDS.
RX   PubMed=19419965; DOI=10.1074/jbc.M901993200;
RA   Phelan M.M., Thai C.-T., Soares D.C., Ogata R.T., Barlow P.N.,
RA   Bramham J.;
RT   "Solution structure of factor I-like modules from complement C7
RT   reveals a pair of follistatin domains in compact pseudosymmetric
RT   arrangement.";
RL   J. Biol. Chem. 284:19637-19649(2009).
RN   [10]
RP   VARIANT C7D SER-521.
RX   PubMed=8871666;
RA   Fernie B.A., Wurzner R., Orren A., Morgan B.P., Potter P.C.,
RA   Platonov A.E., Vershinina I.V., Shipulin G.A., Lachmann P.J.,
RA   Hobart M.J.;
RT   "Molecular bases of combined subtotal deficiencies of C6 and C7: their
RT   effects in combination with other C6 and C7 deficiencies.";
RL   J. Immunol. 157:3648-3657(1996).
RN   [11]
RP   VARIANT C7D ARG-379.
RX   PubMed=9218625;
RA   Fernie B.A., Orren A., Sheehan G., Schlesinger M., Hobart M.J.;
RT   "Molecular bases of C7 deficiency: three different defects.";
RL   J. Immunol. 159:1019-1026(1997).
RN   [12]
RP   VARIANTS C7D GLN-220; GLN-682 AND HIS-687.
RX   PubMed=9856499; DOI=10.1007/s004390050859;
RA   Fernie B.A., Hobart M.J.;
RT   "Complement C7 deficiency: seven further molecular defects and their
RT   associated marker haplotypes.";
RL   Hum. Genet. 103:513-519(1998).
RN   [13]
RP   VARIANTS THR-389 AND PRO-587, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22028381; DOI=10.1093/jmcb/mjr024;
RA   Su Z.D., Sun L., Yu D.X., Li R.X., Li H.X., Yu Z.J., Sheng Q.H.,
RA   Lin X., Zeng R., Wu J.R.;
RT   "Quantitative detection of single amino acid polymorphisms by targeted
RT   proteomics.";
RL   J. Mol. Cell Biol. 3:309-315(2011).
CC   -!- FUNCTION: Constituent of the membrane attack complex (MAC) that
CC       plays a key role in the innate and adaptive immune response by
CC       forming pores in the plasma membrane of target cells. C7 serves as
CC       a membrane anchor.
CC   -!- SUBUNIT: Monomer or dimer; as a C5b-7 complex it can also form
CC       multimeric rosettes. MAC assembly is initiated by proteolytic
CC       cleavage of C5 into C5a and C5b. C5b binds sequentially C6, C7, C8
CC       and multiple copies of the pore-forming subunit C9.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- PTM: C7 has 28 disulfide bridges.
CC   -!- PTM: C-, N- and O-glycosylated. O-glycosylated with core 1 or
CC       possibly core 8 glycans. {ECO:0000269|PubMed:10551839,
CC       ECO:0000269|PubMed:14760718, ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:19139490, ECO:0000269|PubMed:22171320}.
CC   -!- DISEASE: Complement component 7 deficiency (C7D) [MIM:610102]: A
CC       rare defect of the complement classical pathway associated with
CC       susceptibility to severe recurrent infections, predominantly by
CC       Neisseria gonorrhoeae or Neisseria meningitidis.
CC       {ECO:0000269|PubMed:8871666, ECO:0000269|PubMed:9218625,
CC       ECO:0000269|PubMed:9856499}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the complement C6/C7/C8/C9 family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=C7base; Note=C7 mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/C7base/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; J03507; AAA51861.1; -; mRNA.
DR   EMBL; BC063851; AAH63851.1; -; mRNA.
DR   EMBL; X86328; CAA60121.1; -; Genomic_DNA.
DR   EMBL; X86329; CAA60121.1; JOINED; Genomic_DNA.
DR   EMBL; X86330; CAA60121.1; JOINED; Genomic_DNA.
DR   EMBL; X86331; CAA60121.1; JOINED; Genomic_DNA.
DR   EMBL; X86332; CAA60121.1; JOINED; Genomic_DNA.
DR   EMBL; X86333; CAA60121.1; JOINED; Genomic_DNA.
DR   EMBL; X86334; CAA60121.1; JOINED; Genomic_DNA.
DR   EMBL; X86335; CAA60121.1; JOINED; Genomic_DNA.
DR   EMBL; X86336; CAA60121.1; JOINED; Genomic_DNA.
DR   EMBL; X86337; CAA60121.1; JOINED; Genomic_DNA.
DR   EMBL; X86338; CAA60121.1; JOINED; Genomic_DNA.
DR   EMBL; X86339; CAA60121.1; JOINED; Genomic_DNA.
DR   EMBL; X86340; CAA60121.1; JOINED; Genomic_DNA.
DR   EMBL; X86341; CAA60121.1; JOINED; Genomic_DNA.
DR   EMBL; X86342; CAA60121.1; JOINED; Genomic_DNA.
DR   EMBL; X86343; CAA60121.1; JOINED; Genomic_DNA.
DR   EMBL; X86344; CAA60121.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS47201.1; -.
DR   PIR; A27340; A27340.
DR   RefSeq; NP_000578.2; NM_000587.3.
DR   UniGene; Hs.669878; -.
DR   UniGene; Hs.78065; -.
DR   PDB; 2WCY; NMR; -; A=693-843.
DR   PDBsum; 2WCY; -.
DR   ProteinModelPortal; P10643; -.
DR   SMR; P10643; -.
DR   BioGrid; 107191; 4.
DR   CORUM; P10643; -.
DR   IntAct; P10643; 3.
DR   MINT; P10643; -.
DR   STRING; 9606.ENSP00000322061; -.
DR   GlyConnect; 807; -.
DR   iPTMnet; P10643; -.
DR   PhosphoSitePlus; P10643; -.
DR   UniCarbKB; P10643; -.
DR   BioMuta; C7; -.
DR   DMDM; 61252057; -.
DR   PaxDb; P10643; -.
DR   PeptideAtlas; P10643; -.
DR   PRIDE; P10643; -.
DR   ProteomicsDB; 52633; -.
DR   Ensembl; ENST00000313164; ENSP00000322061; ENSG00000112936.
DR   GeneID; 730; -.
DR   KEGG; hsa:730; -.
DR   UCSC; uc003jmh.5; human.
DR   CTD; 730; -.
DR   DisGeNET; 730; -.
DR   EuPathDB; HostDB:ENSG00000112936.18; -.
DR   GeneCards; C7; -.
DR   HGNC; HGNC:1346; C7.
DR   HPA; HPA001465; -.
DR   MalaCards; C7; -.
DR   MIM; 217070; gene.
DR   MIM; 610102; phenotype.
DR   neXtProt; NX_P10643; -.
DR   OpenTargets; ENSG00000112936; -.
DR   Orphanet; 169150; Immunodeficiency due to a late component of complements deficiency.
DR   PharmGKB; PA25941; -.
DR   eggNOG; ENOG410IDXP; Eukaryota.
DR   eggNOG; ENOG410YJ70; LUCA.
DR   GeneTree; ENSGT00550000074478; -.
DR   HOGENOM; HOG000111868; -.
DR   HOVERGEN; HBG005367; -.
DR   InParanoid; P10643; -.
DR   KO; K03996; -.
DR   OMA; NYEFYNS; -.
DR   OrthoDB; EOG091G07LK; -.
DR   PhylomeDB; P10643; -.
DR   TreeFam; TF330498; -.
DR   Reactome; R-HSA-166665; Terminal pathway of complement.
DR   Reactome; R-HSA-977606; Regulation of Complement cascade.
DR   ChiTaRS; C7; human.
DR   EvolutionaryTrace; P10643; -.
DR   GenomeRNAi; 730; -.
DR   PRO; PR:P10643; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000112936; -.
DR   CleanEx; HS_C7; -.
DR   Genevisible; P10643; HS.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005579; C:membrane attack complex; IDA:UniProtKB.
DR   GO; GO:0006883; P:cellular sodium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0006956; P:complement activation; TAS:ProtInc.
DR   GO; GO:0006957; P:complement activation, alternative pathway; IEA:UniProtKB-KW.
DR   GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW.
DR   GO; GO:0019835; P:cytolysis; IEA:UniProtKB-KW.
DR   GO; GO:0030449; P:regulation of complement activation; TAS:Reactome.
DR   CDD; cd00033; CCP; 2.
DR   CDD; cd00112; LDLa; 1.
DR   Gene3D; 2.20.100.10; -; 2.
DR   InterPro; IPR037564; Complement_C7.
DR   InterPro; IPR003884; FacI_MAC.
DR   InterPro; IPR023415; LDLR_class-A_CS.
DR   InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR   InterPro; IPR001862; MAC_perforin.
DR   InterPro; IPR020864; MACPF.
DR   InterPro; IPR020863; MACPF_CS.
DR   InterPro; IPR035976; Sushi/SCR/CCP_sf.
DR   InterPro; IPR000436; Sushi_SCR_CCP_dom.
DR   InterPro; IPR000884; TSP1_rpt.
DR   InterPro; IPR036383; TSP1_rpt_sf.
DR   PANTHER; PTHR19325:SF389; PTHR19325:SF389; 1.
DR   Pfam; PF00057; Ldl_recept_a; 1.
DR   Pfam; PF01823; MACPF; 1.
DR   Pfam; PF00084; Sushi; 2.
DR   Pfam; PF00090; TSP_1; 2.
DR   PRINTS; PR00764; COMPLEMENTC9.
DR   SMART; SM00032; CCP; 2.
DR   SMART; SM00057; FIMAC; 2.
DR   SMART; SM00192; LDLa; 1.
DR   SMART; SM00457; MACPF; 1.
DR   SMART; SM00209; TSP1; 2.
DR   SUPFAM; SSF57535; SSF57535; 2.
DR   SUPFAM; SSF82895; SSF82895; 2.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS01209; LDLRA_1; 1.
DR   PROSITE; PS50068; LDLRA_2; 1.
DR   PROSITE; PS00279; MACPF_1; 1.
DR   PROSITE; PS51412; MACPF_2; 1.
DR   PROSITE; PS50923; SUSHI; 2.
DR   PROSITE; PS50092; TSP1; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Complement alternate pathway; Complement pathway;
KW   Complete proteome; Cytolysis; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; EGF-like domain; Glycoprotein;
KW   Immunity; Innate immunity; Membrane attack complex; Polymorphism;
KW   Reference proteome; Repeat; Secreted; Signal; Sushi.
FT   SIGNAL        1     22
FT   CHAIN        23    843       Complement component C7.
FT                                /FTId=PRO_0000023583.
FT   DOMAIN       27     80       TSP type-1 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN       83    121       LDL-receptor class A.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      124    456       MACPF. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00745}.
FT   DOMAIN      457    487       EGF-like.
FT   DOMAIN      500    549       TSP type-1 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN      569    628       Sushi 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00302}.
FT   DOMAIN      629    690       Sushi 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00302}.
FT   REGION      545    615       CCP 1.
FT   REGION      616    693       CCP 2.
FT   REGION      695    770       Factor I module (FIM) 1.
FT   REGION      771    843       Factor I module (FIM) 2.
FT   CARBOHYD     36     36       C-linked (Man) tryptophan.
FT                                {ECO:0000269|PubMed:10551839}.
FT   CARBOHYD    202    202       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:14760718,
FT                                ECO:0000269|PubMed:16335952}.
FT   CARBOHYD    503    503       C-linked (Man) tryptophan; partial.
FT                                {ECO:0000269|PubMed:10551839}.
FT   CARBOHYD    506    506       C-linked (Man) tryptophan; partial.
FT                                {ECO:0000269|PubMed:10551839}.
FT   CARBOHYD    509    509       C-linked (Man) tryptophan; partial.
FT                                {ECO:0000269|PubMed:10551839}.
FT   CARBOHYD    696    696       O-linked (GalNAc...) threonine.
FT                                {ECO:0000269|PubMed:22171320}.
FT   CARBOHYD    754    754       N-linked (GlcNAc...) (complex)
FT                                asparagine. {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19139490}.
FT   DISULFID     85     96       {ECO:0000250}.
FT   DISULFID     91    109       {ECO:0000250}.
FT   DISULFID    103    119       {ECO:0000250}.
FT   DISULFID    128    165       {ECO:0000250}.
FT   DISULFID    337    353       {ECO:0000269|PubMed:19419965}.
FT   DISULFID    571    613       {ECO:0000250}.
FT   DISULFID    599    626       {ECO:0000250}.
FT   DISULFID    631    673       {ECO:0000250}.
FT   DISULFID    659    688       {ECO:0000250}.
FT   DISULFID    702    713       {ECO:0000269|PubMed:19419965}.
FT   DISULFID    715    750       {ECO:0000269|PubMed:19419965}.
FT   DISULFID    721    743       {ECO:0000269|PubMed:19419965}.
FT   DISULFID    728    763       {ECO:0000269|PubMed:19419965}.
FT   DISULFID    773    782       {ECO:0000269|PubMed:19419965}.
FT   DISULFID    776    789       {ECO:0000269|PubMed:19419965}.
FT   DISULFID    791    825       {ECO:0000269|PubMed:19419965}.
FT   DISULFID    797    818       {ECO:0000269|PubMed:19419965}.
FT   DISULFID    805    838       {ECO:0000269|PubMed:19419965}.
FT   VARIANT     128    128       C -> R (in dbSNP:rs2271708).
FT                                /FTId=VAR_050480.
FT   VARIANT     220    220       R -> Q (in C7D; dbSNP:rs369349760).
FT                                {ECO:0000269|PubMed:9856499}.
FT                                /FTId=VAR_012643.
FT   VARIANT     379    379       G -> R (in C7D; dbSNP:rs121964921).
FT                                {ECO:0000269|PubMed:9218625}.
FT                                /FTId=VAR_012644.
FT   VARIANT     389    389       S -> T (polymorphism; confirmed at
FT                                protein level; dbSNP:rs1063499).
FT                                {ECO:0000269|PubMed:22028381,
FT                                ECO:0000269|PubMed:7730625}.
FT                                /FTId=VAR_033798.
FT   VARIANT     420    420       K -> Q (in dbSNP:rs3792646).
FT                                /FTId=VAR_022023.
FT   VARIANT     521    521       R -> S (in C7D; dbSNP:rs121964920).
FT                                {ECO:0000269|PubMed:8871666}.
FT                                /FTId=VAR_012645.
FT   VARIANT     587    587       T -> P (polymorphism; confirmed at
FT                                protein level; dbSNP:rs13157656).
FT                                {ECO:0000269|PubMed:22028381,
FT                                ECO:0000269|PubMed:3335508}.
FT                                /FTId=VAR_033799.
FT   VARIANT     682    682       E -> Q (in C7D; dbSNP:rs541873000).
FT                                {ECO:0000269|PubMed:9856499}.
FT                                /FTId=VAR_012646.
FT   VARIANT     687    687       R -> H (in C7D; dbSNP:rs113187203).
FT                                {ECO:0000269|PubMed:9856499}.
FT                                /FTId=VAR_012647.
FT   CONFLICT    152    152       R -> V (in Ref. 3; CAA60121).
FT                                {ECO:0000305}.
FT   CONFLICT    821    822       GA -> AL (in Ref. 3). {ECO:0000305}.
FT   STRAND      706    709       {ECO:0000244|PDB:2WCY}.
FT   STRAND      712    715       {ECO:0000244|PDB:2WCY}.
FT   HELIX       718    720       {ECO:0000244|PDB:2WCY}.
FT   STRAND      726    731       {ECO:0000244|PDB:2WCY}.
FT   TURN        732    734       {ECO:0000244|PDB:2WCY}.
FT   STRAND      737    741       {ECO:0000244|PDB:2WCY}.
FT   HELIX       742    750       {ECO:0000244|PDB:2WCY}.
FT   STRAND      755    757       {ECO:0000244|PDB:2WCY}.
FT   STRAND      766    769       {ECO:0000244|PDB:2WCY}.
FT   STRAND      778    782       {ECO:0000244|PDB:2WCY}.
FT   STRAND      784    791       {ECO:0000244|PDB:2WCY}.
FT   HELIX       794    796       {ECO:0000244|PDB:2WCY}.
FT   STRAND      803    808       {ECO:0000244|PDB:2WCY}.
FT   STRAND      811    816       {ECO:0000244|PDB:2WCY}.
FT   HELIX       817    826       {ECO:0000244|PDB:2WCY}.
FT   STRAND      831    836       {ECO:0000244|PDB:2WCY}.
SQ   SEQUENCE   843 AA;  93518 MW;  DBD5D7C92DF71FA5 CRC64;
     MKVISLFILV GFIGEFQSFS SASSPVNCQW DFYAPWSECN GCTKTQTRRR SVAVYGQYGG
     QPCVGNAFET QSCEPTRGCP TEEGCGERFR CFSGQCISKS LVCNGDSDCD EDSADEDRCE
     DSERRPSCDI DKPPPNIELT GNGYNELTGQ FRNRVINTKS FGGQCRKVFS GDGKDFYRLS
     GNVLSYTFQV KINNDFNYEF YNSTWSYVKH TSTEHTSSSR KRSFFRSSSS SSRSYTSHTN
     EIHKGKSYQL LVVENTVEVA QFINNNPEFL QLAEPFWKEL SHLPSLYDYS AYRRLIDQYG
     THYLQSGSLG GEYRVLFYVD SEKLKQNDFN SVEEKKCKSS GWHFVVKFSS HGCKELENAL
     KAASGTQNNV LRGEPFIRGG GAGFISGLSY LELDNPAGNK RRYSAWAESV TNLPQVIKQK
     LTPLYELVKE VPCASVKKLY LKWALEEYLD EFDPCHCRPC QNGGLATVEG THCLCHCKPY
     TFGAACEQGV LVGNQAGGVD GGWSCWSSWS PCVQGKKTRS RECNNPPPSG GGRSCVGETT
     ESTQCEDEEL EHLRLLEPHC FPLSLVPTEF CPSPPALKDG FVQDEGTMFP VGKNVVYTCN
     EGYSLIGNPV ARCGEDLRWL VGEMHCQKIA CVLPVLMDGI QSHPQKPFYT VGEKVTVSCS
     GGMSLEGPSA FLCGSSLKWS PEMKNARCVQ KENPLTQAVP KCQRWEKLQN SRCVCKMPYE
     CGPSLDVCAQ DERSKRILPL TVCKMHVLHC QGRNYTLTGR DSCTLPASAE KACGACPLWG
     KCDAESSKCV CREASECEEE GFSICVEVNG KEQTMSECEA GALRCRGQSI SVTSIRPCAA
     ETQ
//
ID   CO6_HUMAN               Reviewed;         934 AA.
AC   P13671;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2007, sequence version 3.
DT   20-JUN-2018, entry version 190.
DE   RecName: Full=Complement component C6;
DE   Flags: Precursor;
GN   Name=C6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 22-31 AND 633-640.
RX   PubMed=2808363;
RA   Haefliger J.-A., Tschopp J., Vial N., Jenne D.E.;
RT   "Complete primary structure and functional characterization of the
RT   sixth component of the human complement system. Identification of the
RT   C5b-binding domain in complement C6.";
RL   J. Biol. Chem. 264:18041-18051(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT GLU-119.
RX   PubMed=2789218;
RA   Discipio R.G., Hugli T.E.;
RT   "The molecular architecture of human complement component C6.";
RL   J. Biol. Chem. 264:16197-16206(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLU-119.
RC   TISSUE=Blood;
RX   PubMed=8512929; DOI=10.1021/bi00075a012;
RA   Hobart M.J., Fernie B., Discipio R.G.;
RT   "Structure of the human C6 gene.";
RL   Biochemistry 32:6198-6205(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Soejima M., Koda Y.;
RT   "Sequence variation in C6 locus.";
RL   Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLU-119.
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-491, AND VARIANT GLU-119.
RX   PubMed=2468158; DOI=10.1073/pnas.86.8.2799;
RA   Chakravarti D.N., Chakravarti B., Parra C.A., Mueller-Eberhard H.J.;
RT   "Structural homology of complement protein C6 with other channel-
RT   forming proteins of complement.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:2799-2803(1989).
RN   [8]
RP   DISULFIDE BONDS IN FACTOR I MODULE 1 REGION.
RX   PubMed=9366265; DOI=10.1016/S0167-4838(97)00072-1;
RA   Lengweiler S., Schaller J., DiScipio R.G., Rickli E.E.;
RT   "Elucidation of the disulfide-bonding pattern in the factor I modules
RT   of the sixth component (C6) of human complement.";
RL   Biochim. Biophys. Acta 1342:13-18(1997).
RN   [9]
RP   GLYCOSYLATION AT TRP-29; TRP-32; TRP-90; TRP-568; TRP-571 AND TRP-574.
RX   PubMed=10551839; DOI=10.1074/jbc.274.46.32786;
RA   Hofsteenge J., Blommers M., Hess D., Furmanek A., Miroshnichenko O.;
RT   "The four terminal components of the complement system are C-
RT   mannosylated on multiple tryptophan residues.";
RL   J. Biol. Chem. 274:32786-32794(1999).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-324 AND ASN-855.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.87 ANGSTROMS) OF 22-934, GLYCOSYLATION AT
RP   TRP-29; TRP-32; THR-38; ASN-324; THR-392; TRP-568 AND TRP-571,
RP   SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=22267737; DOI=10.1074/jbc.M111.327809;
RA   Aleshin A.E., Schraufstatter I.U., Stec B., Bankston L.A.,
RA   Liddington R.C., DiScipio R.G.;
RT   "Structure of complement C6 suggests a mechanism for initiation and
RT   unidirectional, sequential assembly of membrane attack complex
RT   (MAC).";
RL   J. Biol. Chem. 287:10210-10222(2012).
RN   [13]
RP   VARIANT ALLOTYPE C6 A GLU-119.
RX   PubMed=8101442; DOI=10.1006/bbrc.1993.1841;
RA   Dewald G., Nothen M.M., Cichon S.;
RT   "Polymorphism of human complement component C6: an amino acid
RT   substitution (Glu/Ala) within the second thrombospondin repeat
RT   differentiates between the two common allotypes C6 A and C6 B.";
RL   Biochem. Biophys. Res. Commun. 194:458-464(1993).
RN   [14]
RP   INVOLVEMENT IN COMPLEMENT COMPONENT 6 DEFICIENCY.
RX   PubMed=15565285; DOI=10.1007/s00431-004-1582-y;
RA   Ikinciogullari A., Tekin M., Dogu F., Reisli I., Tanir G., Yi Z.,
RA   Garrison N., Brilliant M.H., Babacan E.;
RT   "Meningococccal meningitis and complement component 6 deficiency
RT   associated with oculocutaneous albinism.";
RL   Eur. J. Pediatr. 164:177-179(2005).
CC   -!- FUNCTION: Constituent of the membrane attack complex (MAC) that
CC       plays a key role in the innate and adaptive immune response by
CC       forming pores in the plasma membrane of target cells.
CC   -!- SUBUNIT: Component of the membrane attack complex (MAC). MAC
CC       assembly is initiated by proteolytic cleavage of C5 into C5a and
CC       C5b. C5b binds sequentially C6, C7, C8 and 12-14 copies of the
CC       pore-forming subunit C9. {ECO:0000269|PubMed:22267737}.
CC   -!- INTERACTION:
CC       P16333:NCK1; NbExp=2; IntAct=EBI-1753221, EBI-389883;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- PTM: All cysteine residues are assumed to be cross-linked to one
CC       another. Individual modules containing an even number of conserved
CC       cysteine residues are supposed to have disulfide linkages only
CC       within the same module.
CC   -!- POLYMORPHISM: The sequence shown is that of allotype C6 B.
CC   -!- DISEASE: Complement component 6 deficiency (C6D) [MIM:612446]: A
CC       rare defect of the complement classical pathway associated with
CC       susceptibility to severe recurrent infections, predominantly by
CC       Neisseria gonorrhoeae or Neisseria meningitidis.
CC       {ECO:0000269|PubMed:15565285}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the complement C6/C7/C8/C9 family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=C6base; Note=C6 mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/C6base/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; J05064; AAA51860.1; -; mRNA.
DR   EMBL; J05024; AAA59668.1; -; mRNA.
DR   EMBL; X72177; CAA50994.1; -; Genomic_DNA.
DR   EMBL; AB126592; BAD02321.1; -; mRNA.
DR   EMBL; AC008863; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC091871; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC035723; AAH35723.1; -; mRNA.
DR   EMBL; J04506; AAB59433.1; -; mRNA.
DR   CCDS; CCDS3936.1; -.
DR   PIR; A34372; A34372.
DR   RefSeq; NP_000056.2; NM_000065.3.
DR   RefSeq; NP_001108603.2; NM_001115131.2.
DR   UniGene; Hs.481992; -.
DR   PDB; 3T5O; X-ray; 2.87 A; A=22-934.
DR   PDB; 4A5W; X-ray; 3.50 A; B=22-934.
DR   PDB; 4E0S; X-ray; 4.21 A; B=22-934.
DR   PDBsum; 3T5O; -.
DR   PDBsum; 4A5W; -.
DR   PDBsum; 4E0S; -.
DR   ProteinModelPortal; P13671; -.
DR   SMR; P13671; -.
DR   BioGrid; 107190; 8.
DR   IntAct; P13671; 5.
DR   STRING; 9606.ENSP00000263413; -.
DR   TCDB; 1.C.39.3.3; the membrane attack complex/perforin (macpf) family.
DR   CarbonylDB; P13671; -.
DR   GlyConnect; 791; -.
DR   iPTMnet; P13671; -.
DR   PhosphoSitePlus; P13671; -.
DR   DMDM; 146345396; -.
DR   EPD; P13671; -.
DR   PaxDb; P13671; -.
DR   PeptideAtlas; P13671; -.
DR   PRIDE; P13671; -.
DR   ProteomicsDB; 52956; -.
DR   DNASU; 729; -.
DR   Ensembl; ENST00000263413; ENSP00000263413; ENSG00000039537.
DR   Ensembl; ENST00000337836; ENSP00000338861; ENSG00000039537.
DR   GeneID; 729; -.
DR   KEGG; hsa:729; -.
DR   UCSC; uc003jmk.4; human.
DR   CTD; 729; -.
DR   DisGeNET; 729; -.
DR   EuPathDB; HostDB:ENSG00000039537.13; -.
DR   GeneCards; C6; -.
DR   H-InvDB; HIX0024838; -.
DR   HGNC; HGNC:1339; C6.
DR   HPA; CAB069427; -.
DR   HPA; HPA043823; -.
DR   MalaCards; C6; -.
DR   MIM; 217050; gene.
DR   MIM; 612446; phenotype.
DR   neXtProt; NX_P13671; -.
DR   OpenTargets; ENSG00000039537; -.
DR   Orphanet; 169150; Immunodeficiency due to a late component of complements deficiency.
DR   PharmGKB; PA25921; -.
DR   eggNOG; ENOG410IDXP; Eukaryota.
DR   eggNOG; ENOG410YJ70; LUCA.
DR   GeneTree; ENSGT00550000074478; -.
DR   HOGENOM; HOG000111865; -.
DR   HOVERGEN; HBG005366; -.
DR   InParanoid; P13671; -.
DR   KO; K03995; -.
DR   OMA; CKNKFRC; -.
DR   OrthoDB; EOG091G07LK; -.
DR   PhylomeDB; P13671; -.
DR   TreeFam; TF330498; -.
DR   Reactome; R-HSA-166665; Terminal pathway of complement.
DR   Reactome; R-HSA-977606; Regulation of Complement cascade.
DR   ChiTaRS; C6; human.
DR   GeneWiki; Complement_component_6; -.
DR   GenomeRNAi; 729; -.
DR   PRO; PR:P13671; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000039537; -.
DR   CleanEx; HS_C6; -.
DR   ExpressionAtlas; P13671; baseline and differential.
DR   Genevisible; P13671; HS.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005579; C:membrane attack complex; IDA:UniProtKB.
DR   GO; GO:0006956; P:complement activation; TAS:ProtInc.
DR   GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW.
DR   GO; GO:0019835; P:cytolysis; IEA:UniProtKB-KW.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0001970; P:positive regulation of activation of membrane attack complex; IEA:Ensembl.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0030449; P:regulation of complement activation; TAS:Reactome.
DR   CDD; cd00033; CCP; 2.
DR   CDD; cd00112; LDLa; 1.
DR   Gene3D; 2.20.100.10; -; 3.
DR   InterPro; IPR037563; Complement_C6.
DR   InterPro; IPR003884; FacI_MAC.
DR   InterPro; IPR002350; Kazal_dom.
DR   InterPro; IPR036055; LDL_receptor-like_sf.
DR   InterPro; IPR023415; LDLR_class-A_CS.
DR   InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR   InterPro; IPR001862; MAC_perforin.
DR   InterPro; IPR020864; MACPF.
DR   InterPro; IPR020863; MACPF_CS.
DR   InterPro; IPR035976; Sushi/SCR/CCP_sf.
DR   InterPro; IPR000436; Sushi_SCR_CCP_dom.
DR   InterPro; IPR000884; TSP1_rpt.
DR   InterPro; IPR036383; TSP1_rpt_sf.
DR   PANTHER; PTHR19325:SF23; PTHR19325:SF23; 1.
DR   Pfam; PF00057; Ldl_recept_a; 1.
DR   Pfam; PF01823; MACPF; 1.
DR   Pfam; PF00084; Sushi; 2.
DR   Pfam; PF00090; TSP_1; 3.
DR   PRINTS; PR00764; COMPLEMENTC9.
DR   SMART; SM00032; CCP; 2.
DR   SMART; SM00057; FIMAC; 2.
DR   SMART; SM00192; LDLa; 1.
DR   SMART; SM00457; MACPF; 1.
DR   SMART; SM00209; TSP1; 3.
DR   SUPFAM; SSF57424; SSF57424; 1.
DR   SUPFAM; SSF57535; SSF57535; 2.
DR   SUPFAM; SSF82895; SSF82895; 3.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS51465; KAZAL_2; 2.
DR   PROSITE; PS01209; LDLRA_1; 1.
DR   PROSITE; PS50068; LDLRA_2; 1.
DR   PROSITE; PS00279; MACPF_1; 1.
DR   PROSITE; PS51412; MACPF_2; 1.
DR   PROSITE; PS50923; SUSHI; 2.
DR   PROSITE; PS50092; TSP1; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Complement pathway; Complete proteome; Cytolysis;
KW   Direct protein sequencing; Disulfide bond; EGF-like domain;
KW   Glycoprotein; Immunity; Innate immunity; Membrane attack complex;
KW   Polymorphism; Reference proteome; Repeat; Secreted; Signal; Sushi.
FT   SIGNAL        1     21       {ECO:0000269|PubMed:2808363}.
FT   CHAIN        22    934       Complement component C6.
FT                                /FTId=PRO_0000023579.
FT   DOMAIN       22     79       TSP type-1 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN       81    134       TSP type-1 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN      138    175       LDL-receptor class A.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      176    522       MACPF. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00745}.
FT   DOMAIN      523    553       EGF-like.
FT   DOMAIN      565    612       TSP type-1 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN      642    701       Sushi 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00302}.
FT   DOMAIN      702    763       Sushi 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00302}.
FT   DOMAIN      780    839       Kazal-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00798}.
FT   DOMAIN      876    934       Kazal-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00798}.
FT   REGION      611    688       CCP 1.
FT   REGION      642    934       C5b-binding domain.
FT   REGION      689    765       CCP 2.
FT   REGION      766    840       Factor I module (FIM) 1.
FT   REGION      858    934       Factor I module (FIM) 2.
FT   CARBOHYD     29     29       C-linked (Man) tryptophan.
FT                                {ECO:0000269|PubMed:10551839}.
FT   CARBOHYD     32     32       C-linked (Man) tryptophan; partial.
FT                                {ECO:0000269|PubMed:10551839}.
FT   CARBOHYD     38     38       O-linked (Fuc...) threonine.
FT                                {ECO:0000305|PubMed:22267737}.
FT   CARBOHYD     90     90       C-linked (Man) tryptophan; partial.
FT                                {ECO:0000269|PubMed:10551839}.
FT   CARBOHYD    324    324       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:22267737}.
FT   CARBOHYD    392    392       O-linked (Fuc...) threonine.
FT                                {ECO:0000305|PubMed:22267737}.
FT   CARBOHYD    568    568       C-linked (Man) tryptophan; partial.
FT                                {ECO:0000269|PubMed:10551839}.
FT   CARBOHYD    571    571       C-linked (Man) tryptophan; partial.
FT                                {ECO:0000269|PubMed:10551839}.
FT   CARBOHYD    574    574       C-linked (Man) tryptophan; partial.
FT                                {ECO:0000269|PubMed:10551839}.
FT   CARBOHYD    855    855       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952}.
FT   DISULFID     22     61
FT   DISULFID     24     65
FT   DISULFID     35     73
FT   DISULFID     39     78
FT   DISULFID     82    117
FT   DISULFID     93    127
FT   DISULFID     96    133
FT   DISULFID    140    151
FT   DISULFID    146    164
FT   DISULFID    158    173
FT   DISULFID    180    218
FT   DISULFID    399    420
FT   DISULFID    499    623
FT   DISULFID    521    570
FT   DISULFID    523    539
FT   DISULFID    526    541
FT   DISULFID    543    552
FT   DISULFID    577    611
FT   DISULFID    589    601
FT   DISULFID    644    686
FT   DISULFID    672    699
FT   DISULFID    704    746
FT   DISULFID    732    761
FT   DISULFID    773    823
FT   DISULFID    784    801
FT   DISULFID    786    837
FT   DISULFID    793    816
FT   DISULFID    862    873
FT   DISULFID    867    919
FT   DISULFID    880    897
FT   DISULFID    882    932
FT   DISULFID    888    912
FT   VARIANT     119    119       A -> E (in allotype C6 A;
FT                                dbSNP:rs1801033).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:2468158,
FT                                ECO:0000269|PubMed:2789218,
FT                                ECO:0000269|PubMed:8101442,
FT                                ECO:0000269|PubMed:8512929}.
FT                                /FTId=VAR_006056.
FT   VARIANT     397    397       K -> E (in dbSNP:rs6896011).
FT                                /FTId=VAR_027647.
FT   VARIANT     470    470       S -> F (in dbSNP:rs10462014).
FT                                /FTId=VAR_027648.
FT   CONFLICT    567    567       Q -> H (in Ref. 4; BAD02321).
FT                                {ECO:0000305}.
FT   CONFLICT    616    616       M -> I (in Ref. 4; BAD02321).
FT                                {ECO:0000305}.
FT   CONFLICT    934    934       A -> T (in Ref. 4; BAD02321).
FT                                {ECO:0000305}.
FT   HELIX        24     26       {ECO:0000244|PDB:3T5O}.
FT   STRAND       38     40       {ECO:0000244|PDB:3T5O}.
FT   STRAND       42     48       {ECO:0000244|PDB:3T5O}.
FT   HELIX        54     58       {ECO:0000244|PDB:3T5O}.
FT   HELIX        61     64       {ECO:0000244|PDB:3T5O}.
FT   STRAND       68     73       {ECO:0000244|PDB:3T5O}.
FT   STRAND       95     97       {ECO:0000244|PDB:3T5O}.
FT   STRAND      100    104       {ECO:0000244|PDB:4A5W}.
FT   STRAND      106    108       {ECO:0000244|PDB:3T5O}.
FT   STRAND      121    125       {ECO:0000244|PDB:4A5W}.
FT   STRAND      130    133       {ECO:0000244|PDB:3T5O}.
FT   STRAND      141    145       {ECO:0000244|PDB:3T5O}.
FT   STRAND      151    153       {ECO:0000244|PDB:3T5O}.
FT   HELIX       154    156       {ECO:0000244|PDB:3T5O}.
FT   STRAND      157    161       {ECO:0000244|PDB:3T5O}.
FT   STRAND      164    167       {ECO:0000244|PDB:3T5O}.
FT   HELIX       168    170       {ECO:0000244|PDB:3T5O}.
FT   STRAND      179    182       {ECO:0000244|PDB:3T5O}.
FT   HELIX       190    194       {ECO:0000244|PDB:3T5O}.
FT   STRAND      195    198       {ECO:0000244|PDB:3T5O}.
FT   TURN        199    202       {ECO:0000244|PDB:3T5O}.
FT   STRAND      203    207       {ECO:0000244|PDB:3T5O}.
FT   STRAND      226    228       {ECO:0000244|PDB:3T5O}.
FT   STRAND      236    240       {ECO:0000244|PDB:3T5O}.
FT   HELIX       247    249       {ECO:0000244|PDB:3T5O}.
FT   STRAND      250    256       {ECO:0000244|PDB:3T5O}.
FT   HELIX       258    262       {ECO:0000244|PDB:3T5O}.
FT   STRAND      279    282       {ECO:0000244|PDB:4A5W}.
FT   TURN        287    289       {ECO:0000244|PDB:3T5O}.
FT   HELIX       298    307       {ECO:0000244|PDB:3T5O}.
FT   STRAND      309    327       {ECO:0000244|PDB:3T5O}.
FT   STRAND      329    331       {ECO:0000244|PDB:3T5O}.
FT   HELIX       336    341       {ECO:0000244|PDB:3T5O}.
FT   HELIX       351    361       {ECO:0000244|PDB:3T5O}.
FT   STRAND      363    365       {ECO:0000244|PDB:3T5O}.
FT   STRAND      367    382       {ECO:0000244|PDB:3T5O}.
FT   HELIX       383    389       {ECO:0000244|PDB:3T5O}.
FT   HELIX       393    407       {ECO:0000244|PDB:3T5O}.
FT   HELIX       418    420       {ECO:0000244|PDB:3T5O}.
FT   HELIX       426    429       {ECO:0000244|PDB:3T5O}.
FT   HELIX       434    436       {ECO:0000244|PDB:3T5O}.
FT   STRAND      437    442       {ECO:0000244|PDB:3T5O}.
FT   STRAND      445    447       {ECO:0000244|PDB:3T5O}.
FT   HELIX       449    455       {ECO:0000244|PDB:3T5O}.
FT   STRAND      461    465       {ECO:0000244|PDB:3T5O}.
FT   HELIX       466    478       {ECO:0000244|PDB:3T5O}.
FT   STRAND      481    486       {ECO:0000244|PDB:3T5O}.
FT   STRAND      487    489       {ECO:0000244|PDB:4A5W}.
FT   HELIX       490    493       {ECO:0000244|PDB:3T5O}.
FT   HELIX       500    516       {ECO:0000244|PDB:3T5O}.
FT   HELIX       520    522       {ECO:0000244|PDB:3T5O}.
FT   TURN        527    529       {ECO:0000244|PDB:3T5O}.
FT   STRAND      530    535       {ECO:0000244|PDB:3T5O}.
FT   STRAND      538    542       {ECO:0000244|PDB:3T5O}.
FT   STRAND      547    549       {ECO:0000244|PDB:4A5W}.
FT   HELIX       550    552       {ECO:0000244|PDB:4A5W}.
FT   STRAND      579    586       {ECO:0000244|PDB:3T5O}.
FT   STRAND      595    597       {ECO:0000244|PDB:3T5O}.
FT   STRAND      605    610       {ECO:0000244|PDB:3T5O}.
FT   STRAND      643    645       {ECO:0000244|PDB:4A5W}.
FT   STRAND      653    656       {ECO:0000244|PDB:3T5O}.
FT   STRAND      660    663       {ECO:0000244|PDB:4A5W}.
FT   STRAND      667    672       {ECO:0000244|PDB:3T5O}.
FT   STRAND      676    680       {ECO:0000244|PDB:3T5O}.
FT   STRAND      683    686       {ECO:0000244|PDB:3T5O}.
FT   STRAND      688    692       {ECO:0000244|PDB:4A5W}.
FT   STRAND      698    701       {ECO:0000244|PDB:3T5O}.
FT   STRAND      703    705       {ECO:0000244|PDB:3T5O}.
FT   STRAND      711    714       {ECO:0000244|PDB:3T5O}.
FT   STRAND      715    717       {ECO:0000244|PDB:4A5W}.
FT   STRAND      720    723       {ECO:0000244|PDB:3T5O}.
FT   STRAND      727    729       {ECO:0000244|PDB:3T5O}.
FT   STRAND      734    736       {ECO:0000244|PDB:4A5W}.
FT   STRAND      737    740       {ECO:0000244|PDB:3T5O}.
FT   STRAND      742    745       {ECO:0000244|PDB:3T5O}.
FT   STRAND      747    749       {ECO:0000244|PDB:4A5W}.
FT   STRAND      755    757       {ECO:0000244|PDB:4A5W}.
FT   TURN        772    776       {ECO:0000244|PDB:3T5O}.
FT   STRAND      778    783       {ECO:0000244|PDB:4A5W}.
FT   HELIX       789    792       {ECO:0000244|PDB:3T5O}.
FT   STRAND      798    804       {ECO:0000244|PDB:3T5O}.
FT   TURN        805    808       {ECO:0000244|PDB:3T5O}.
FT   STRAND      809    814       {ECO:0000244|PDB:3T5O}.
FT   HELIX       815    822       {ECO:0000244|PDB:3T5O}.
FT   HELIX       825    827       {ECO:0000244|PDB:3T5O}.
FT   STRAND      829    836       {ECO:0000244|PDB:3T5O}.
FT   HELIX       841    851       {ECO:0000244|PDB:3T5O}.
FT   STRAND      853    857       {ECO:0000244|PDB:4A5W}.
FT   STRAND      862    864       {ECO:0000244|PDB:3T5O}.
FT   STRAND      875    877       {ECO:0000244|PDB:3T5O}.
FT   STRAND      879    881       {ECO:0000244|PDB:3T5O}.
FT   HELIX       885    891       {ECO:0000244|PDB:4A5W}.
FT   STRAND      897    899       {ECO:0000244|PDB:3T5O}.
FT   STRAND      901    903       {ECO:0000244|PDB:3T5O}.
FT   STRAND      905    907       {ECO:0000244|PDB:3T5O}.
FT   HELIX       911    920       {ECO:0000244|PDB:3T5O}.
FT   STRAND      925    930       {ECO:0000244|PDB:3T5O}.
SQ   SEQUENCE   934 AA;  104786 MW;  A88F4BED7CC349D3 CRC64;
     MARRSVLYFI LLNALINKGQ ACFCDHYAWT QWTSCSKTCN SGTQSRHRQI VVDKYYQENF
     CEQICSKQET RECNWQRCPI NCLLGDFGPW SDCDPCIEKQ SKVRSVLRPS QFGGQPCTAP
     LVAFQPCIPS KLCKIEEADC KNKFRCDSGR CIARKLECNG ENDCGDNSDE RDCGRTKAVC
     TRKYNPIPSV QLMGNGFHFL AGEPRGEVLD NSFTGGICKT VKSSRTSNPY RVPANLENVG
     FEVQTAEDDL KTDFYKDLTS LGHNENQQGS FSSQGGSSFS VPIFYSSKRS ENINHNSAFK
     QAIQASHKKD SSFIRIHKVM KVLNFTTKAK DLHLSDVFLK ALNHLPLEYN SALYSRIFDD
     FGTHYFTSGS LGGVYDLLYQ FSSEELKNSG LTEEEAKHCV RIETKKRVLF AKKTKVEHRC
     TTNKLSEKHE GSFIQGAEKS ISLIRGGRSE YGAALAWEKG SSGLEEKTFS EWLESVKENP
     AVIDFELAPI VDLVRNIPCA VTKRNNLRKA LQEYAAKFDP CQCAPCPNNG RPTLSGTECL
     CVCQSGTYGE NCEKQSPDYK SNAVDGQWGC WSSWSTCDAT YKRSRTRECN NPAPQRGGKR
     CEGEKRQEED CTFSIMENNG QPCINDDEEM KEVDLPEIEA DSGCPQPVPP ENGFIRNEKQ
     LYLVGEDVEI SCLTGFETVG YQYFRCLPDG TWRQGDVECQ RTECIKPVVQ EVLTITPFQR
     LYRIGESIEL TCPKGFVVAG PSRYTCQGNS WTPPISNSLT CEKDTLTKLK GHCQLGQKQS
     GSECICMSPE EDCSHHSEDL CVFDTDSNDY FTSPACKFLA EKCLNNQQLH FLHIGSCQDG
     RQLEWGLERT RLSSNSTKKE SCGYDTCYDW EKCSASTSKC VCLLPPQCFK GGNQLYCVKM
     GSSTSEKTLN ICEVGTIRCA NRKMEILHPG KCLA
//
ID   CO9_RAT                 Reviewed;         554 AA.
AC   Q62930; Q62957;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   23-MAY-2018, entry version 127.
DE   RecName: Full=Complement component C9;
DE   Flags: Precursor;
GN   Name=C9;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND DEVELOPMENTAL STAGE.
RC   STRAIN=Sprague-Dawley;
RX   PubMed=9212048; DOI=10.1203/00006450-199707000-00020;
RA   Lassiter H.A., Walz B.M., Wilson J.L., Jung E., Calisi C.R.,
RA   Goldsmith L.J., Wilson R.A., Morgan B.P., Feldhoff R.C.;
RT   "The administration of complement component C9 enhances the survival
RT   of neonatal rats with Escherichia coli sepsis.";
RL   Pediatr. Res. 42:128-136(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley;
RA   Hinchliffe S.J., Van den Berg C.W., Rushmere N.K., Morgan B.P.;
RT   "Cloning of rat C9: consequences for homologous restriction of
RT   complement.";
RL   Submitted (MAR-1996) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Constituent of the membrane attack complex (MAC) that
CC       plays a key role in the innate and adaptive immune response by
CC       forming pores in the plasma membrane of target cells. C9 is the
CC       pore-forming subunit of the MAC. {ECO:0000269|PubMed:9212048}.
CC   -!- SUBUNIT: Component of the membrane attack complex (MAC). MAC
CC       assembly is initiated by proteolytic cleavage of C5 into C5a and
CC       C5b. C5b binds sequentially C6, C7, C8 and multiple copies of the
CC       pore-forming subunit C9. About 20 C9 chains oligomerize to give
CC       rise to a huge beta-barrel that forms a 100 Angstrom diameter pore
CC       in target membranes. {ECO:0000250|UniProtKB:P02748}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:9212048}.
CC       Target cell membrane {ECO:0000269|PubMed:9212048}; Multi-pass
CC       membrane protein {ECO:0000250|UniProtKB:P02748}. Note=Secreted as
CC       soluble monomer. Oligomerizes at target membranes, forming a pre-
CC       pore. A conformation change then leads to the formation of a 100
CC       Angstrom diameter pore. {ECO:0000250|UniProtKB:P02748}.
CC   -!- TISSUE SPECIFICITY: Detected in blood serum (at protein level).
CC       {ECO:0000269|PubMed:9212048}.
CC   -!- DEVELOPMENTAL STAGE: Detected at low levels in neonate blood
CC       serum. Levels increase throughout the first three weeks after
CC       birth. {ECO:0000269|PubMed:9212048}.
CC   -!- SIMILARITY: Belongs to the complement C6/C7/C8/C9 family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA96528.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; U49071; AAB38023.1; -; mRNA.
DR   EMBL; U52948; AAA96528.1; ALT_INIT; mRNA.
DR   RefSeq; NP_476487.1; NM_057146.1.
DR   UniGene; Rn.10252; -.
DR   ProteinModelPortal; Q62930; -.
DR   SMR; Q62930; -.
DR   BioGrid; 250734; 1.
DR   STRING; 10116.ENSRNOP00000018545; -.
DR   iPTMnet; Q62930; -.
DR   PhosphoSitePlus; Q62930; -.
DR   PaxDb; Q62930; -.
DR   PRIDE; Q62930; -.
DR   GeneID; 117512; -.
DR   KEGG; rno:117512; -.
DR   CTD; 735; -.
DR   RGD; 620319; C9.
DR   eggNOG; ENOG410IH3C; Eukaryota.
DR   eggNOG; ENOG410XT9A; LUCA.
DR   HOVERGEN; HBG106792; -.
DR   InParanoid; Q62930; -.
DR   KO; K04000; -.
DR   PMAP-CutDB; Q62930; -.
DR   PRO; PR:Q62930; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005579; C:membrane attack complex; IEA:UniProtKB-KW.
DR   GO; GO:0044218; C:other organism cell membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0007596; P:blood coagulation; IMP:RGD.
DR   GO; GO:0006957; P:complement activation, alternative pathway; IEA:UniProtKB-KW.
DR   GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW.
DR   GO; GO:0019835; P:cytolysis; IEA:UniProtKB-KW.
DR   CDD; cd00112; LDLa; 1.
DR   InterPro; IPR037567; Complement_C9.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR036055; LDL_receptor-like_sf.
DR   InterPro; IPR023415; LDLR_class-A_CS.
DR   InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR   InterPro; IPR001862; MAC_perforin.
DR   InterPro; IPR020864; MACPF.
DR   InterPro; IPR020863; MACPF_CS.
DR   InterPro; IPR000884; TSP1_rpt.
DR   InterPro; IPR036383; TSP1_rpt_sf.
DR   PANTHER; PTHR19325:SF362; PTHR19325:SF362; 1.
DR   Pfam; PF00057; Ldl_recept_a; 1.
DR   Pfam; PF01823; MACPF; 1.
DR   Pfam; PF00090; TSP_1; 1.
DR   PRINTS; PR00764; COMPLEMENTC9.
DR   SMART; SM00192; LDLa; 1.
DR   SMART; SM00457; MACPF; 1.
DR   SMART; SM00209; TSP1; 1.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   SUPFAM; SSF57424; SSF57424; 1.
DR   SUPFAM; SSF82895; SSF82895; 1.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01209; LDLRA_1; 1.
DR   PROSITE; PS50068; LDLRA_2; 1.
DR   PROSITE; PS00279; MACPF_1; 1.
DR   PROSITE; PS51412; MACPF_2; 1.
DR   PROSITE; PS50092; TSP1; 1.
PE   1: Evidence at protein level;
KW   Complement alternate pathway; Complement pathway; Complete proteome;
KW   Cytolysis; Disulfide bond; EGF-like domain; Glycoprotein; Immunity;
KW   Innate immunity; Membrane; Membrane attack complex;
KW   Reference proteome; Secreted; Signal; Target cell membrane;
KW   Target membrane; Transmembrane; Transmembrane beta strand.
FT   SIGNAL        1     20       {ECO:0000255}.
FT   CHAIN        21    554       Complement component C9.
FT                                /FTId=PRO_0000023607.
FT   TRANSMEM    316    332       Beta stranded. {ECO:0000255}.
FT   TRANSMEM    337    356       Beta stranded. {ECO:0000255}.
FT   DOMAIN       40     93       TSP type-1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN       97    134       LDL-receptor class A.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      136    518       MACPF. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00745}.
FT   DOMAIN      519    549       EGF-like.
FT   SITE        267    268       Cleavage; by thrombin.
FT   CARBOHYD    261    261       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    409    409       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    423    423       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     41     76       {ECO:0000250}.
FT   DISULFID     52     55       {ECO:0000250}.
FT   DISULFID     86     92       {ECO:0000250}.
FT   DISULFID     99    110       {ECO:0000250}.
FT   DISULFID    105    123       {ECO:0000250}.
FT   DISULFID    117    132       {ECO:0000250}.
FT   DISULFID    140    179       {ECO:0000250}.
FT   DISULFID    382    413       {ECO:0000250}.
FT   DISULFID    519    535       {ECO:0000250}.
FT   DISULFID    522    537       {ECO:0000250}.
FT   DISULFID    539    548       {ECO:0000250}.
FT   CONFLICT     65     65       I -> M (in Ref. 2; AAA96528).
FT                                {ECO:0000305}.
FT   CONFLICT    300    300       K -> R (in Ref. 2; AAA96528).
FT                                {ECO:0000305}.
SQ   SEQUENCE   554 AA;  62281 MW;  9C885F76A1275649 CRC64;
     MASGVTITLA IAIFALEINA QAPEPTPREE PSADALLPID CRMSTWSQWS QCDPCLKQRF
     RSRSIEVFGQ FQGKSCADAL GDRQHCEPTQ ECEEVQENCG NDFQCETGRC IKRKLLCNGD
     NDCGDFSDES DCESDPRLPC RDRVVEESEL GRTAGYGINI LGMDPLGTPF DNEFYNGLCD
     RVRDGNTLTY YRKPWNVAFL AYETKADKNF RTENYEEQFE MFKTIVRDRT TSFNANLALK
     FTITEAPIKK VGVDEVSPEK NSSKPKDSSV DFQFSYFKKE NFQRLSSYLS QTKKMFLHVK
     GMIQLGRFVM RNRGVMLTTT FLDDVKALPV SYEKGEYFGF LETYGTHYSS SGSLGGLYEL
     IYVLDKASMK EKGVELSDVK RCLGFNLDVS LYTPLQTALE GPSLTANVNH SDCLKTGDGK
     VVNISRDHII DDVISFIRGG TRKQAVLLKE KLLRGAKTID VNDFINWASS LDDAPALISQ
     KLSPIYNLIP LTMKDAYAKK QNMEKAIEDY VNEFSARKCY PCQNGGTAIL LDGQCMCSCT
     IKFKGIACEI SKQR
//
ID   CO8G_MOUSE              Reviewed;         202 AA.
AC   Q8VCG4;
DT   19-SEP-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2002, sequence version 1.
DT   20-JUN-2018, entry version 130.
DE   RecName: Full=Complement component C8 gamma chain;
DE   Flags: Precursor;
GN   Name=C8g;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Mammary tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [2]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-158 AND ASN-173.
RC   STRAIN=C57BL/6J; TISSUE=Plasma;
RX   PubMed=16944957; DOI=10.1021/pr060186m;
RA   Ghesquiere B., Van Damme J., Martens L., Vandekerckhove J.,
RA   Gevaert K.;
RT   "Proteome-wide characterization of N-glycosylation events by diagonal
RT   chromatography.";
RL   J. Proteome Res. 5:2438-2447(2006).
RN   [3]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brown adipose tissue, Heart, Kidney, Liver, Lung, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
CC   -!- FUNCTION: C8 is a constituent of the membrane attack complex. C8
CC       binds to the C5B-7 complex, forming the C5B-8 complex. C5-B8 binds
CC       C9 and acts as a catalyst in the polymerization of C9. The gamma
CC       subunit seems to be able to bind retinol (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBUNIT: C8 is composed of three chains: alpha, beta and gamma.
CC       The alpha and gamma chains are disulfide bonded (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- SIMILARITY: Belongs to the calycin superfamily. Lipocalin family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; BC019967; AAH19967.1; -; mRNA.
DR   CCDS; CCDS15777.1; -.
DR   RefSeq; NP_081338.1; NM_027062.2.
DR   UniGene; Mm.24596; -.
DR   ProteinModelPortal; Q8VCG4; -.
DR   SMR; Q8VCG4; -.
DR   BioGrid; 213399; 1.
DR   STRING; 10090.ENSMUSP00000041855; -.
DR   iPTMnet; Q8VCG4; -.
DR   PhosphoSitePlus; Q8VCG4; -.
DR   MaxQB; Q8VCG4; -.
DR   PaxDb; Q8VCG4; -.
DR   PeptideAtlas; Q8VCG4; -.
DR   PRIDE; Q8VCG4; -.
DR   Ensembl; ENSMUST00000040042; ENSMUSP00000041855; ENSMUSG00000015083.
DR   GeneID; 69379; -.
DR   KEGG; mmu:69379; -.
DR   UCSC; uc008isi.2; mouse.
DR   CTD; 733; -.
DR   MGI; MGI:88237; C8g.
DR   eggNOG; ENOG410IX6K; Eukaryota.
DR   eggNOG; ENOG4111Y9C; LUCA.
DR   GeneTree; ENSGT00440000034309; -.
DR   HOGENOM; HOG000111143; -.
DR   HOVERGEN; HBG005369; -.
DR   InParanoid; Q8VCG4; -.
DR   KO; K03999; -.
DR   OMA; GSACRFL; -.
DR   OrthoDB; EOG091G0QPN; -.
DR   PhylomeDB; Q8VCG4; -.
DR   TreeFam; TF336103; -.
DR   Reactome; R-MMU-166665; Terminal pathway of complement.
DR   Reactome; R-MMU-977606; Regulation of Complement cascade.
DR   PRO; PR:Q8VCG4; -.
DR   Proteomes; UP000000589; Chromosome 2.
DR   Bgee; ENSMUSG00000015083; -.
DR   CleanEx; MM_C8G; -.
DR   ExpressionAtlas; Q8VCG4; baseline and differential.
DR   Genevisible; Q8VCG4; MM.
DR   GO; GO:0005576; C:extracellular region; ISO:MGI.
DR   GO; GO:0005615; C:extracellular space; ISO:MGI.
DR   GO; GO:0005579; C:membrane attack complex; IEA:UniProtKB-KW.
DR   GO; GO:0001848; F:complement binding; ISO:MGI.
DR   GO; GO:0044877; F:protein-containing complex binding; ISO:MGI.
DR   GO; GO:0019841; F:retinol binding; IEA:UniProtKB-KW.
DR   GO; GO:0006957; P:complement activation, alternative pathway; IEA:UniProtKB-KW.
DR   GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW.
DR   GO; GO:0019835; P:cytolysis; ISO:MGI.
DR   Gene3D; 2.40.128.20; -; 1.
DR   InterPro; IPR002968; A1-microglobln.
DR   InterPro; IPR012674; Calycin.
DR   InterPro; IPR002345; Lipocalin.
DR   InterPro; IPR022272; Lipocalin_CS.
DR   InterPro; IPR000566; Lipocln_cytosolic_FA-bd_dom.
DR   PANTHER; PTHR11430; PTHR11430; 1.
DR   Pfam; PF00061; Lipocalin; 1.
DR   PRINTS; PR01215; A1MCGLOBULIN.
DR   SUPFAM; SSF50814; SSF50814; 1.
DR   PROSITE; PS00213; LIPOCALIN; 1.
PE   1: Evidence at protein level;
KW   Complement alternate pathway; Complement pathway; Complete proteome;
KW   Cytolysis; Disulfide bond; Glycoprotein; Immunity; Innate immunity;
KW   Membrane attack complex; Pyrrolidone carboxylic acid;
KW   Reference proteome; Retinol-binding; Secreted; Signal.
FT   SIGNAL        1     20       {ECO:0000255}.
FT   CHAIN        21    202       Complement component C8 gamma chain.
FT                                /FTId=PRO_0000017882.
FT   MOD_RES      21     21       Pyrrolidone carboxylic acid.
FT                                {ECO:0000250|UniProtKB:P07360}.
FT   CARBOHYD     41     41       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    158    158       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16944957}.
FT   CARBOHYD    173    173       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16944957}.
FT   DISULFID     60     60       Interchain (with C-194 in C8-alpha
FT                                chain). {ECO:0000250}.
FT   DISULFID     96    188       {ECO:0000250}.
SQ   SEQUENCE   202 AA;  22508 MW;  CA7E08B1B663CE50 CRC64;
     MLSPGAVLFF TLLLTASSLG QRTRKPIGST SPISTIQAQV NFSAQKFAGT WLLVAVGSSC
     RFLQEQGHRA EATTLHAAPQ GAAMAVSTFR KLDGICWQVR QLFENTGVPG RFLFQVSRAR
     GPVHMVVAET DYQSFAILYL EQGRKLSVKL YVRSLPVNDS VLDVFERRVR EANLTEDQIL
     FFPKYGFCET ADQLHILNEV PR
//
ID   CO8B_ONCMY              Reviewed;         587 AA.
AC   Q90X85;
DT   23-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   20-JUN-2018, entry version 89.
DE   RecName: Full=Complement component C8 beta chain;
DE   AltName: Full=Complement component 8 subunit beta;
DE   Flags: Precursor;
GN   Name=c8b;
OS   Oncorhynchus mykiss (Rainbow trout) (Salmo gairdneri).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Actinopterygii; Neopterygii; Teleostei; Protacanthopterygii;
OC   Salmoniformes; Salmonidae; Salmoninae; Oncorhynchus.
OX   NCBI_TaxID=8022;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=12590968; DOI=10.1016/S0145-305X(02)00092-7;
RA   Kazantzi A., Sfyroera G., Holland M.C.H., Lambris J.D., Zarkadis I.K.;
RT   "Molecular cloning of the beta subunit of complement component eight
RT   of rainbow trout.";
RL   Dev. Comp. Immunol. 27:167-174(2003).
CC   -!- FUNCTION: Constituent of the membrane attack complex (MAC) that
CC       plays a key role in the innate and adaptive immune response by
CC       forming pores in the plasma membrane of target cells.
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Heterotrimer of 3 chains: alpha, beta and gamma. The
CC       alpha and gamma chains are disulfide bonded. Component of the
CC       membrane attack complex (MAC). MAC assembly is initiated by
CC       proteolytic cleavage of C5 into C5a and C5b. C5b sequentially
CC       binds C6, C7, C8 and multiple copies of the pore-forming subunit
CC       C9 (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the complement C6/C7/C8/C9 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; AF418597; AAL16647.1; -; mRNA.
DR   RefSeq; NP_001118079.1; NM_001124607.1.
DR   UniGene; Omy.7987; -.
DR   ProteinModelPortal; Q90X85; -.
DR   SMR; Q90X85; -.
DR   PRIDE; Q90X85; -.
DR   GeneID; 100136625; -.
DR   CTD; 732; -.
DR   HOVERGEN; HBG106489; -.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005579; C:membrane attack complex; IEA:UniProtKB-KW.
DR   GO; GO:0006957; P:complement activation, alternative pathway; IEA:UniProtKB-KW.
DR   GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW.
DR   GO; GO:0019835; P:cytolysis; IEA:UniProtKB-KW.
DR   CDD; cd00112; LDLa; 1.
DR   Gene3D; 2.20.100.10; -; 2.
DR   InterPro; IPR037566; Complement_C8_beta.
DR   InterPro; IPR036055; LDL_receptor-like_sf.
DR   InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR   InterPro; IPR001862; MAC_perforin.
DR   InterPro; IPR020864; MACPF.
DR   InterPro; IPR020863; MACPF_CS.
DR   InterPro; IPR000884; TSP1_rpt.
DR   InterPro; IPR036383; TSP1_rpt_sf.
DR   PANTHER; PTHR19325:SF401; PTHR19325:SF401; 1.
DR   Pfam; PF00057; Ldl_recept_a; 1.
DR   Pfam; PF01823; MACPF; 1.
DR   PRINTS; PR00764; COMPLEMENTC9.
DR   SMART; SM00192; LDLa; 1.
DR   SMART; SM00457; MACPF; 1.
DR   SMART; SM00209; TSP1; 2.
DR   SUPFAM; SSF57424; SSF57424; 1.
DR   SUPFAM; SSF82895; SSF82895; 2.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS50068; LDLRA_2; 1.
DR   PROSITE; PS00279; MACPF_1; 1.
DR   PROSITE; PS51412; MACPF_2; 1.
DR   PROSITE; PS50092; TSP1; 2.
PE   2: Evidence at transcript level;
KW   Complement alternate pathway; Complement pathway; Cytolysis;
KW   Disulfide bond; EGF-like domain; Glycoprotein; Immunity;
KW   Innate immunity; Membrane attack complex; Repeat; Secreted; Signal.
FT   SIGNAL        1     31       {ECO:0000255}.
FT   PROPEP       32     44       {ECO:0000250}.
FT                                /FTId=PRO_0000023597.
FT   CHAIN        45    587       Complement component C8 beta chain.
FT                                /FTId=PRO_0000023598.
FT   DOMAIN       56    111       TSP type-1 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN      117    159       LDL-receptor class A.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      154    500       MACPF. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00745}.
FT   DOMAIN      501    531       EGF-like.
FT   DOMAIN      541    587       TSP type-1 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   CARBOHYD     62     62       C-linked (Man) tryptophan.
FT                                {ECO:0000250|UniProtKB:P07358}.
FT   CARBOHYD     65     65       C-linked (Man) tryptophan.
FT                                {ECO:0000250|UniProtKB:P07358}.
FT   CARBOHYD    547    547       C-linked (Man) tryptophan.
FT                                {ECO:0000250|UniProtKB:P07358}.
FT   CARBOHYD    550    550       C-linked (Man) tryptophan.
FT                                {ECO:0000250|UniProtKB:P07358}.
FT   DISULFID     57     92       {ECO:0000250}.
FT   DISULFID     68     71       {ECO:0000250}.
FT   DISULFID    102    110       {ECO:0000250}.
FT   DISULFID    118    129       {ECO:0000250}.
FT   DISULFID    123    142       {ECO:0000250}.
FT   DISULFID    136    158       {ECO:0000250}.
FT   DISULFID    374    399       {ECO:0000250}.
SQ   SEQUENCE   587 AA;  65540 MW;  6D80417659FC879E CRC64;
     MNHKLKPTVG LGYCLLCAAL CLLLLRDVAI AGSGEEPSGV REARSVGTQV AVQPVDCVQS
     EWSSWTRCDV CRKKRYRYAK LVQPSQFGGE PCHVQGKEVE PCSPPSRYDC THDETPLCEG
     FLCTYTGRCV PIDLRCNGDD DCGDWSAEKG SPKVPKACKQ EAQEYHGIEN LAKGINILHS
     HLEGSVIDNR YYAGSCLPHY IQDVRFRKPY NLQQYTLETK GTYDFKLQSF ESYSEFVHYT
     MTERSSKTTV SIGFALPGVA EFGFNYADSK YSKSEKKIRR ASRKENSFVQ AKAELQLARY
     ILKSEDLMLH PEFFLRLRAL PQSYNYGEYR QIYRDYGTHY ITEATLGGDY EYTVILDKEK
     LEKTGYSLEA YKNCEQIVLK VGANIKGVYV TVGLEGGGCD GLLNEMGEDT VKGSMVEDYV
     AVVSGGDSES ITWLAAKNLP TPPLMRLWGE AVHYNLDFIR SVTRPLYELV TARDFSSANS
     LKKNLRRALA EYLEESSSCR CAPCRNNGLA VLKGTRCECV CPSGYSGLGC EITQRPDIGI
     DGSWSCWGSW SPCRGRSKTR SRQCNNPAPS SGGIACRGLQ METTDCF
//
ID   CO7_PIG                 Reviewed;         843 AA.
AC   Q9TUQ3;
DT   19-SEP-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   28-FEB-2018, entry version 104.
DE   RecName: Full=Complement component C7;
DE   Flags: Precursor;
GN   Name=C7;
OS   Sus scrofa (Pig).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;
OC   Sus.
OX   NCBI_TaxID=9823;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 640-651, FUNCTION,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Lung;
RX   PubMed=10878384; DOI=10.4049/jimmunol.165.2.1059;
RA   Agah A., Montalto M.C., Kiesecker C.L., Morrissey M., Grover M.,
RA   Whoolery K.L., Rother R.P., Stahl G.L.;
RT   "Isolation, characterization, and cloning of porcine complement
RT   component C7.";
RL   J. Immunol. 165:1059-1065(2000).
CC   -!- FUNCTION: Constituent of the membrane attack complex (MAC) that
CC       plays a key role in the innate and adaptive immune response by
CC       forming pores in the plasma membrane of target cells. C7 serves as
CC       a membrane anchor. {ECO:0000269|PubMed:10878384}.
CC   -!- SUBUNIT: Monomer or dimer; as a C5b-7 complex it can also form
CC       multimeric rosettes. MAC assembly is initiated by proteolytic
CC       cleavage of C5 into C5a and C5b. C5b binds sequentially C6, C7, C8
CC       and multiple copies of the pore-forming subunit C9 (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:10878384}.
CC   -!- TISSUE SPECIFICITY: Detected in plasma (at protein level). Bone
CC       marrow, heart, intestine, lung, spleen, kidney, liver and thymus.
CC       {ECO:0000269|PubMed:10878384}.
CC   -!- PTM: C7 has 28 disulfide bridges. {ECO:0000250}.
CC   -!- PTM: C- and N-glycosylated. {ECO:0000250|UniProtKB:P10643}.
CC   -!- SIMILARITY: Belongs to the complement C6/C7/C8/C9 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; AF162274; AAD45918.1; -; mRNA.
DR   RefSeq; NP_999447.1; NM_214282.1.
DR   UniGene; Ssc.5836; -.
DR   ProteinModelPortal; Q9TUQ3; -.
DR   SMR; Q9TUQ3; -.
DR   STRING; 9823.ENSSSCP00000017865; -.
DR   PaxDb; Q9TUQ3; -.
DR   PeptideAtlas; Q9TUQ3; -.
DR   PRIDE; Q9TUQ3; -.
DR   GeneID; 397526; -.
DR   KEGG; ssc:397526; -.
DR   CTD; 730; -.
DR   eggNOG; ENOG410IDXP; Eukaryota.
DR   eggNOG; ENOG410YJ70; LUCA.
DR   HOGENOM; HOG000111868; -.
DR   HOVERGEN; HBG005367; -.
DR   InParanoid; Q9TUQ3; -.
DR   KO; K03996; -.
DR   Proteomes; UP000008227; Unplaced.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005579; C:membrane attack complex; IEA:UniProtKB-KW.
DR   GO; GO:0006957; P:complement activation, alternative pathway; IEA:UniProtKB-KW.
DR   GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW.
DR   GO; GO:0019835; P:cytolysis; IEA:UniProtKB-KW.
DR   CDD; cd00033; CCP; 2.
DR   CDD; cd00112; LDLa; 1.
DR   Gene3D; 2.20.100.10; -; 2.
DR   InterPro; IPR037564; Complement_C7.
DR   InterPro; IPR003884; FacI_MAC.
DR   InterPro; IPR036055; LDL_receptor-like_sf.
DR   InterPro; IPR023415; LDLR_class-A_CS.
DR   InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR   InterPro; IPR001862; MAC_perforin.
DR   InterPro; IPR020864; MACPF.
DR   InterPro; IPR020863; MACPF_CS.
DR   InterPro; IPR035976; Sushi/SCR/CCP_sf.
DR   InterPro; IPR000436; Sushi_SCR_CCP_dom.
DR   InterPro; IPR000884; TSP1_rpt.
DR   InterPro; IPR036383; TSP1_rpt_sf.
DR   PANTHER; PTHR19325:SF389; PTHR19325:SF389; 1.
DR   Pfam; PF00057; Ldl_recept_a; 1.
DR   Pfam; PF01823; MACPF; 1.
DR   Pfam; PF00084; Sushi; 2.
DR   Pfam; PF00090; TSP_1; 2.
DR   PRINTS; PR00764; COMPLEMENTC9.
DR   SMART; SM00032; CCP; 2.
DR   SMART; SM00057; FIMAC; 2.
DR   SMART; SM00192; LDLa; 1.
DR   SMART; SM00457; MACPF; 1.
DR   SMART; SM00209; TSP1; 2.
DR   SUPFAM; SSF57424; SSF57424; 1.
DR   SUPFAM; SSF57535; SSF57535; 2.
DR   SUPFAM; SSF82895; SSF82895; 2.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS01209; LDLRA_1; 1.
DR   PROSITE; PS50068; LDLRA_2; 1.
DR   PROSITE; PS00279; MACPF_1; 1.
DR   PROSITE; PS51412; MACPF_2; 1.
DR   PROSITE; PS50923; SUSHI; 2.
DR   PROSITE; PS50092; TSP1; 2.
PE   1: Evidence at protein level;
KW   Complement alternate pathway; Complement pathway; Complete proteome;
KW   Cytolysis; Direct protein sequencing; Disulfide bond; EGF-like domain;
KW   Glycoprotein; Immunity; Innate immunity; Membrane attack complex;
KW   Reference proteome; Repeat; Secreted; Signal; Sushi.
FT   SIGNAL        1     22       {ECO:0000250}.
FT   CHAIN        23    843       Complement component C7.
FT                                /FTId=PRO_0000023584.
FT   DOMAIN       27     80       TSP type-1 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN       83    121       LDL-receptor class A.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      124    456       MACPF. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00745}.
FT   DOMAIN      457    487       EGF-like.
FT   DOMAIN      500    549       TSP type-1 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00210}.
FT   DOMAIN      569    628       Sushi 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00302}.
FT   DOMAIN      629    690       Sushi 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00302}.
FT   REGION      545    615       CCP 1.
FT   REGION      616    693       CCP 2.
FT   REGION      695    770       Factor I module (FIM) 1.
FT   REGION      771    843       Factor I module (FIM) 2.
FT   CARBOHYD     36     36       C-linked (Man) tryptophan.
FT                                {ECO:0000250|UniProtKB:P10643}.
FT   CARBOHYD    202    202       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    503    503       C-linked (Man) tryptophan.
FT                                {ECO:0000250|UniProtKB:P10643}.
FT   CARBOHYD    506    506       C-linked (Man) tryptophan.
FT                                {ECO:0000250|UniProtKB:P10643}.
FT   CARBOHYD    509    509       C-linked (Man) tryptophan.
FT                                {ECO:0000250|UniProtKB:P10643}.
FT   CARBOHYD    754    754       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     85     96       {ECO:0000250}.
FT   DISULFID     91    109       {ECO:0000250}.
FT   DISULFID    103    119       {ECO:0000250}.
FT   DISULFID    128    165       {ECO:0000250}.
FT   DISULFID    337    353       {ECO:0000250}.
FT   DISULFID    571    613       {ECO:0000250}.
FT   DISULFID    599    626       {ECO:0000250}.
FT   DISULFID    631    673       {ECO:0000250}.
FT   DISULFID    659    688       {ECO:0000250}.
FT   DISULFID    702    713       {ECO:0000250}.
FT   DISULFID    715    750       {ECO:0000250}.
FT   DISULFID    721    743       {ECO:0000250}.
FT   DISULFID    728    763       {ECO:0000250}.
FT   DISULFID    773    782       {ECO:0000250}.
FT   DISULFID    776    789       {ECO:0000250}.
FT   DISULFID    791    825       {ECO:0000250}.
FT   DISULFID    797    818       {ECO:0000250}.
FT   DISULFID    805    838       {ECO:0000250}.
SQ   SEQUENCE   843 AA;  93062 MW;  0B703D93C3E5C83D CRC64;
     MKAMSLVFLV GLIGEFQVFS SASSPVNCQW DSYAPWSECN GCTKTQTRRR PVAVYGQYGG
     HPCVGSTFET QSCEPTRGCP TEEGCGERFR CFSGQCISKS LVCNGDSDCE EDSADEDRCE
     DSESRPSCDL SKPPPNIELT GNGYNALTGQ FRNRVLNTKS FGGQCRKVFS GDGRDFYRLS
     GNVLSYTFQV KVNNDFNYEF YNSTWSYAKH TSTEHTSSSK GRVFIFSSSS SSSSYYAKTY
     EILKKKSYQL LVVQNTVEVA QFINNNPEFL QLAESFWKEL SYLPPLYDYS AYRRLIDQYG
     THYLQSGSLG GEYKVLFYVD SEKVAESDLG SEDKKKCASS HISFLFKSSK HKCKAMEEAL
     KSASGTQSNV LRGVPFVRGG RPGFVSGLSY LELDNPDGNK QRYSSWAGSV TDLPQVIKQK
     LTPLYELVKE VPCASVKRLY LKRALEEYLD EFDSCHCQPC QNGGMASVEG TQCQCHCKPN
     TFGVACEQGV LVGDHAGGID GGWSCWSSWG PCAQGKKTRS RKCNNPPPSG GGKSCIGETS
     ESRQCEDEDL EHLRLLEPHC FPLSLVPTEF CPSPPALKDG FVQNEETTFP VGKNIVYSCN
     EGYSLVGDPV ARCGEDLQWT VGKMHCQKIA CVLPTLMRGL QSHPQKPFYT VGEKVTFSCS
     SGMSLEGPST FLCGSSLKWS PEMKNVQCVR KEAPLAKKVP ECQLWEKLQN SKCVCKMPYE
     CGSSLDVCAR DERSKRILRL TVCKMHVLQC QGRNYTLSVG ETCTLPGSAE KACGACPLWE
     KCDAQSSKCV CRAASECEEA GFRVCVEVNG REQTMTECEA GVLRCLGLSI TVTSIRPCAP
     EAP
//
